学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

鈴木祐介（スズキユウスケ）

研究テーマ	腎臓内科
研究業績（論文）	英文原著 1.Suzuki Y, Takeda Y, Sato D, Kanaguchi Y, Tanaka Y, Kobayashi S, Suzuki K, Hashimoto H, Ozaki S, Horikoshi S, Tomino Y. Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan. Mod Rheumatol. 20:54-62, 2010. 2.Suzuki Y, Kanaguchi Y, Ken Osaki, Takeshi Sugaya, Satoshi Horikoshi, Yasuhiko Tomino. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis. (1st and 2nd authors equally contributed to this paper.) Nephrol Dial Transplant. 26:3465-3473, 2011 3.Tomino Y, Shimizu Y, Hamada C, Kurusu A, Ohsawa I, Suzuki Y, Tsuge T, Ito H, Kobayashi N, Takeda Y, Asanuma K, Tanaka Y, Suzuki H, Nakata J, Takara K, Horikoshi S. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease. J Nephrol 24:756-763, 2011. 4.Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, Tomino Y. Pathological role of tonsillar B cells in IgA nephropathy. Clin Dev Immunol. 2011:639074, 2011. 5.Suzuki Y, Suzuki H, Sato D, Kajiyama T, Okazaki K, Hashimoto A, Kihara M, Yamaji K, Satake K, Nakata J, Aizawa M, Novak J, Tomino Y. Reevaluation of the mucosa-bone marrow axis in IgA nephropathy with animal models. Adv Otorhinolaryngol. 72:64-67, 2011 6.Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, Horikoshi S, Ikeda K, Tomino Y. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant. 27:1090-1097, 2012 2012 (in press) 7.Okazaki K, Suzuki Y, Otsuji M, Suzuki H, Kihara M, Kajiyama T, Hashimoto A, Nishimura H, Brown R, Hall S, Novak J, Izui S, Hirose S, Tomino Y. Establishment of a novel ddY mouse model with early onset IgA nephropathy. J Am Soc Nephrol. 23:1364-1374, 2012 8.Hashimoto A, Suzuki Y, Suzuki H, Ohsawa I, Brown R, Hall S, TanakaY, Novak J, Ohi H, Tomino Y. Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am J Pathol, 181:1338-1347, 2012 9.hi S, Novak J, Tomino Y.Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Horikos Nephrol Dial Transplant. 2012 (in press) 10.Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, Matsuo S, Tomino Y. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. 2013 (in press) 11.Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2013 Aug 4. [Epub ahead of print] 12.Osaki K, Suzuki Y, Sugaya T, Tanifuji C, Nishiyama A, Horikoshi S, Tomino Y. Amelioration of Angiotensin II-Induced Salt-Sensitive Hypertension by Liver-Type Fatty Acid-Binding Protein in Proximal Tubules. Hypertension. 2013 62:712-8. doi: 10.1161/HYPERTENSIONAHA.113.01203, 2013 13.Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y. Serum levels of galactose deficient IgA1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol. 2014 (in press) 14.Suzuki Y, Nakata J, Hitoshi Suzuki, Daisuke Sato, Tatsuya Kano, Hiroyuki Yanagawa, Keiichi Matsuzaki, Satoshi Horikoshi, Jan Novak, Yasuhiko Tomino. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. (1st and 2nd authors equally contributed to this paper.) PLOS ONE 9(2):e89707. doi: 10.1371/journal.pone.0089707. eCollection 2014. 15.Maiguma M, Suzuki Y, Suzuki H, Okazaki K, Aizawa M, Muto M, Tomino Y. Dietary zinc is a key environmental modifier in the progression of IgA nephropathy. PLOS ONE. 9(2):e90558. doi: 10.1371/journal.pone.0090558. eCollection 2014. 16.Aizawa M, Suzuki Y, Suzuki H, Pang H, Kihara M, Nakata J, Yamaji K, Horikoshi S, Tomino Y. Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy. PLOS ONE. 9(4):e95365. doi: 10.1371/journal.pone.0095365. eCollection 2014. 17.Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLOS ONE. 9(5):e98081. doi: 10.1371/journal.pone.0098081. eCollection 2014. 18.Satake K, Shimizu Y, Sasaki Y, Yanagawa H, Suzuki H, Suzuki Y, Horikoshi S, Honda S, Shibuya K, Shibuya A, Tomino Y Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy. BMC Nephrol. 15:89, 2014 19.Suzuki Y, Suzuki H, Makita Y, Takahata A, Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H, Okazaki K, Tomino Y. Diagnosis and activity assessment of IgA nephropathy: current perspectives on non-invasive testing with aberrantly glycosylated IgA-related biomarkers. Int J Nephrol and Renovasc Dis. 2014 20.Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y. The kinetics of glomerular deposition of nephritogenic IgA. PLOS ONE. 2014 19;9(11):e113005. doi: 10.1371/journal.pone.0113005. eCollection 2014. 21.Makita Y, Tanaka Y, Shimizu Y, Takeda Y, Kanamaru Y, Ohsawa I, Suzuki Y, Kurusu A, Horikoshi S, Tomino Y. A case of Fabry disease, in which renal symptoms served as a diagnostic prompt. Juntendo Medical Journal 2014 60: 353-357. 22.Suzuki Y, Suzuki H, Yasutake J, Tomino Y. Paradigm shift in activity assessment of IgA nephropathy–optimizing the next generation of diagnostic and therapeutic maneuvers via glycan-targeting. Expert Opinion on Biological Therapy 2015 20:1-11 23.Suzuki H, Suzuki Y, Novak J, Tomino Y. Development of Animal Models of Human IgA Nephropathy. Drug Discov Today Dis Models. 2014 Spring;11:5-11. 24.Suzuki Y, Yasutake J, Suzuki H, Hiura N, Yanaga Hwa1, Makita Y, Kaneko E, Tomino Y. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA Nephropathy. Nephrol Dial Transplant. 30: 1315-1321,2015 (1st and 2nd authors are equally contributed to this work) 25.Chunbei L, Kanamaru Y, Watanabe T, Tada N, Horikoshi S, Suzuki Y, Zhihong L, Tomino Y: Targeted IgA Fc Receptor I (FcαRI) Therapy in the Early Intervention and Treatment of Pristane Induced Lupus Nephritis in Mice. Clin Exp Immunol.181:407-416, 2015 26.Yang Gyun K, Alvarez M, Suzuki H, Hirose S, Izui S, Tomino Y, Bertrand H, Suzuki Y: Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS One 10:e0137044, 2015 27.Kamijo S, Nunomura S, Ra C, Kanaguchi Y, Suzuki Y, Ogawa H, Okumura K, Takai T: Innate basophil IL-4 responses against allergens, endotoxin, and cytokines require the Fc receptor  -chain. J Allergy Clin Immun, pii: S0091-6749(15)01671-1, 2015 28.Yamanaka T, Tamauchi H, Suzuki Y, Suzuki H, Horikoshi S, Terashima M, Iwabuchi K, Habu S, Okumura K, Tomino Y: Release from Th1-type immune tolerance in spleen and enhanced production of IL-5 in Peyer's patch by cholera toxin B induce the glomerular deposition of IgA.　 Immunobiology, 221:577-85, 2016 29.Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z,Wyatt RJ, Novak J, Julian BA: Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? Dis Markers 2016: 7806438, 2016 30.Suzuki H, Kihara M, Mano S, Kobayashi T, Kanaguchi Y, Hidaka T, Gohda T, Suzuki Y: Efficacy and Safety of Denosumab for the Treatment of Osteoporosis in Patients with Chronic Kidney Disease. Clin Exp Nephrol 2017 (in press) 31.Atikemu K, Suzuki Y, Otsuji M, Horikoshi S, Tomino Y: Influence of Estrogen on the Progression of Kindney Injury in Murine IgA Nephropathy. Juntendo Medical Journal 63: 178-185,2017 32.Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakui S, Righini C, Maiguma M, Izui S, Tomino Y, Huard B, Suzuki Y: Toll-like Receptor 9 Stimulation lnduces Aberrant Expression of a Proliferation-lnducing Ligand by Tonsillar Germinal Center B Cell in IgA Nephropathy. J Am Soc Nephrol 28: 1227-1238, 2017 33.Sasaki Y, Hidaka T, Ueno T, Akiba-Takagi M, Trejo JA, Seki T, Nagai-Hosoe Y, Tanaka E, Horikoshi S, Tomino Y, Suzuki Y, Asanuma K: Sorting Nexin 9 facilitates podocin endocytosis in the injured podocyte. Sci Rep 7: 43921, 2017 34.Hara K, Hamada C, Wakabayashi K, Kanda R, Kaneko K, Horikoshi S, Tomino Y, Suzuki Y: Scavenging of reactive oxygen species by astaxanthin inhibits epithelial-mesenchymal transition in high glucose-stimulated mesothelial cells. Plos One 12: e0184332, 2017 35.Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z, Kiryluk K, Suzuki Y, Wyatt RJ, Tomino Y, Gharavi AG, Weinmann A, Julian BA, Willey CD, Novak J: Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. Kidney Int Rep 2: 1194-1207, 2017 36.Inoue MK,Yamamotoya T, Nakatsu Y, Ueda K,1 Yuki Inoue Y, Matsunaga Y,　Sakoda H, Fujishiro M, Ono H, Morii K, Sasaki K, Masaki T, SuzukiY, Asano T, Kushiyama A: The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. Int J Mol Sci.19(12): 3967-3980, 2018 37.Ohsawa I, Honda D, Hisada A, Inoshita H, Onda-Tsueshita K, Mano S, Sato N, Nakamura Y, Shimizu T, Gotoh H, Goto Y, Suzuki Y, Tomino Y: Clinical Features of Hereditary and Mast Cell-mediated Angioedema Focusing on the Differential Diagnosis in Japanese Patients. Intern Med, 57; 319-324 2018 38.Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamazaki K, Sofue T, Kano T, Suzuki Y: IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1 oriented pathogenesis. Kidney Int, 93: 700-705, 2018 39.Asao R, Seki T, Takagi M, Yamada H, Kodama F, Hosoe-Nagai Y, Tanaka E, Trejo JAO, Yamamoto-Nonaka K, Sasaki Y, Hidaka T, Ueno T, Yanagita M, Suzuki Y, Tomino Y, Asanuma K : Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis. Sci Rep. 8(1):5061, 2018 40.Suzuki Y: B Cells in IgAN and the Rationale for B Cell Directed Therapies in IgAN. Kidney Diseases. 4:145-194, 2018. 41.Io H, Suzuki Y.: Strategy for Prevention of Left Ventricular Remodeling in Predialysis and Dialysis Patients. Contrib Nephrol. 196：13-21, 2018. 42.Thaha M, Empitu MA, Kadariswantiningsih IN, Nugroho CW, Hasanatulidhhiyah N, Rasyid H, EI Hakim Z, Suryansyah MM, Alda RR, Alsagaff MY, Amin M, Santoso D, Suzuki Y.: Anthropometry-based Body Fat Percentage Predicts High hs-CRP in Chronic Kidney Disease Patients. Indones Biomed J. 10(2):184-191, 2018. 43.Sato D, Gohda T, Kihara M, Kanaguchi Y, Kobayashi T, Mano S, Sasaki Y, Nohara N, Murakoshi M, Nakata J, Suzuki H, Ueda S, Horikoshi S, Suzuki Y.: Effect of Zinc Acetate Dihydrate (Nobelzin®) Tretement on Anemia and Taste Disorders in Patients with Chronic Kidney Disease with　Hypozincemia. Acta Medica Okayama. 72;（5）: 535-538, 2018. 44.Suzuki H, Suzuki Y.: Murine Models of Human IgA Nephropathy. Semin Nephrol. 38 (5): 513 – 520, 2018. 45.Takahashi K, Ueda K, Kobayashi T, Nishiyama A, Fujisawa T, Sugaya T, Shiota S, Takahashi K, Gohda T, Horikoshi S, Suzuki Y. Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease. Sci Rep. 8(1):17926, 2018. 46.Yamasaki K, Suzuki H, Yasutake J, Yamasaki Y, Suzuki Y. Galactose-Deficient IgA1-Specific Antibody Recognizes GalNAc-Modified Unique Epitope on Hinge Region of IgA1. Monoclon Antib Immunodiagn Immunother. 37(6):252-256, 2018. 47.Honda D, Suzuki Y. Mass media information can facilitate early diagnose of hereditary angioedema. Orphanet J of Rare Disease. 2019 in press 48.Hirano K, Matsuzaki K, YasudaT, Nishikawa M, YasudaY, Koike K, Maruyama S, Yokoo T, Matsuo S,Kawamura,T, Suzuki Y: Association between tonsillectomy and outcomes in patients with Immunoglobulin a nephropathy. JAMA Netw　 Open. 2019;2(5): e194772doi: 10.1001/　jamanetworkopen.2019.4772 49.Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC, International IgA Nephropathy Network.：JAMA Intern Med. 2019 Apr 13. doi: 10.1001/ jamainternmed.2019.0600. 50.Neufeld M, Molyneux K, Pappelbaum KI, Mayer-Hain S, von Hodenberg C, Ehrchen J, Barratt J, Suzuki Y, Sunderkötter C: Galactose deficient IgA1 (GD-IgA1) in skin and serum from patients with skin-limited and systemic IgA Vasculitis. J Am Acad Dermatol 81(5):1078-1085,2019 51.Shimizu Y, Wakabayashi K, Hayashi Y, Hara K, Aoyama R, Niimi Y, Tomino Y, Wada R, Hata M, Suzuki Y: MPGN type 3 associated with pemphigus herpetiformis mimicking PGNMID and dermatitis herpetiformis. Case Rep Nephrol Dial. 9(1):15-24,2019 52.Wakabayashi K, Yanagawa H, Hayashi Y, Aoyama R, Shimizu Y, Tomino Y, Suzuki Y: Progressive renal dysfunction due to IgG4-related kidney disease that is refractory to steroid therapy. Case Rep Nephrol Dial. 9(1):1-7,2019 53.Shimizu Y, Wakabayashi K, Totsuka A, Hayashi Y, Nitta S, Hara K, Akira M, Tomino Y, Suzuki Y: Exercise-induced acute kidney injury (EAKI) in a police officer with hereditary renal hypouricemia. Case Rep Nephrol Dial. 9(2):92–101,2019 54.Io H, Nakata J, Aoyama R, Inoshita H, Nakano T, Ishizaka M, Fukui M, Tomino Y, Suzuki Y: Far-infrared therapy for secondary vascular access patency of hemodialysis patients. Renal Replacement Theraphy 5:30,2019 55.Koshida T, Wu S, Suzuki H, Wanchoo R, Bijol V, Tomita S, Suzuki Y, Jhaveri K: Thrombotic Microangiopathy in Dasatinib-treated patients with Chronic Myeloid Leukemia. Journal of Onco-Nephrology 1-5,2019 56.Makita Y, Suzuki H, Suzuki Y: TLR9 activation induces aberrant IgA glycosylation via APRIL-and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 97(2)340-349,2020 57.Gohda T, Kamei N, Koshida T, Kubota M, Tanaka K, Yamashita Y, Adachi E, Ichikawa S, Murakoshi M, Ueda S, Suzuki Y: Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease. J Diabetes Invest. 11(2):435-440,2020 58.Ichikawa S, Gohda T, Murakoshi M, Li Z, Adachi E, Koshida T, Suzuki Y: Aspartic Acid Supplementation Ameliorates Symptoms of Diabetic Kidney Disease in Mice. FEBS Open Bio. doi: 10.1002/2211-5463.12862, 2020 59.Hara K, Io H, Wakabayashi K, Maeda T, Kanda R, Nakata J, Maeda K, Sengoku H, Machida M, Kojima K, Sakamoto K, Tomino Y, Suzuki Y: Multicenter Laparoscopic Evaluation of the Peritoneum in Peritoneal Dialysis Patients. Semin Dial. 33(2):170-177, 2020 60.Takahata A, Arai S, Hiramoto E, Kitada K, Kato R, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y: Crucial role of AIM/CD5L in the development of glomerular inflammation in IgA. J Am Soc Nephrol., 2020 (in press) 61.Wu CY, Hua KF , Hsu WH, Suzuki Y, Chu LJ, Lee YC , Takahata　A, Lee SL , Wu CC, Nikolic-Paterson DJ , Ka SM , Chen A : IgA Nephropathy Benefits From Compound K Treatment by Inhibiting NF-κB/NLRP3 Inflammasome and Enhancing Autophagy and SIRT1. J Immunol. 2020 Jun 1;ji1900284. doi: 10.4049/ jimmunol.1900284. 62.Shirai Y, Miura K, Yabuuchi T, Nagasawa T, Ishizuka K, Takahashi K, Taneda S, Honda K, Yamaguchi Y, Suzuki H, Suzuki Y, Hattori M : Rapid Progression to End-Stage Renal Disease in a Child With IgA-dominant Infection-Related Glomerulonephritis Associated With Parvovirus B19, CEN Case Rep. 2020 Jul 3. doi: 10.1007/s13730-020-00501- w. Online ahead of print. PMID: 32621069 63.Kubo A, Hidaka T, Nakayama M, Sasaki Y, Takagi M, Suzuki H, Suzuki Y:　　Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases, BMC Nephrol.,21:402-415, 2020 64.Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, Maruyama S, Yokoo T, Matsuo S, Kawamura T, Suzuki Y: Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy, JAMA Netw Open, 2:e194772, 2020 65.Li Z, Murakoshi M, Ichikawa S, Koshida T, Adachi E, Suzuki C, Ueda S, Tomohito Gohda T, Suzuki Y: The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice, FEBS Open Bio. doi: 10.1002/2211-5463.13014, 2020 66.Io H, Nakata J , Inoshita H, Ishizaka M, Tomino Y, Suzuk Y: Relationship among left ventricular hypertrophy, cardiovascular events, and preferred blood pressure measurement timing in hemodialysis patients, J. Clin. Med. 9:3512-3521, 2020 67.Murakoshi M, Gohda T, Suzuki Y: Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease. Int J Mol Sci. 21(6):1957, 2020 68.Kobayashi T, Ueda S, Takagi M, Kihara M, Suzuki Y: Pathophysiological roles of ADMAmediated endothelial injury in hypertensive disorders of pregnancy.Hypertens Res Pregnancy,in press, 2020 69.Honda D, Ohsawa I, Mano S, Rinno H, Tomino Y, Suzuki Y： Cut-off value of C1-inhibitor function for the diagnosis of hereditary angioedema due to C1-inhibitor deficiency. Intractable Rare Dis Res,10:42-47, 2020 70.Lee M, Suzuki H, Kato R, Fukao Y, Nakayama M, Kano T, Makita Y, Suzuki Y: Renal pathological analysis using galactose deficient IgA1-specific monoclonal antibody is a strong tool for differentiation primary IgA nephropathy from secondary IgA nephropathy, CEN Case Rep. 10:17-22, 2021 71.Kobayashi T, Ueda S, Takahashi K, Otsuka T, Nagasawa H, Yabuuchi J, Kanaguchi Y, Sugaya T, Urabe T, Tomino Y, Suzuki Y: Ischemic stroke induces rapid renal oxidative stress and lipometabolic change. Juntendo Medical Journal, 67: 39-45, 2021 72.Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Induruwage D, Er L, Reich HN, Feehally J, Barratt J, Cattran DC; International IgA Nephropathy NetworkImproving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney Int. 98:1009-1019 73.Shimizu Y, Nakata J, Yanagawa N, Shirotani Y, Fukuzaki H, Nohara N, Suzuki Y: Emergent initiation of dialysis is related to an increase in both mortality and medical costs. Sci Rep. 10:19638, 2020 74.Yabuuchi J, Ueda S, Yamagishi S, Nohara N, Nagasawa H, Wakabayashi K, Matsui T, Higashimoto Y, Kadoguchi T, Otsuka T, Gohda T, Suzuki Y: Assosiation of advanced glycation end products with sarcopenia and frailty in chronic kidney disease. Sci Rep. 10:17647, 2020 75.Kuwasawa-Iwasaki M, Io H, Muto M, Ichikawa S, Wakabayashi K, Kanda R, Nakata J, Nohara N, Tomino Y, Suzuki Y: Effects of L-Carnitine Supplementation in Patients Receiving Hemodialysis or Peritoneal Dialysis. Nutrients. 12(11):3371, 2020 76.Shimizu Y, Nakata J, Maiguma M, Shirotani Y, Fukuzaki H, Nohara N, Io H, Suzuki Y: Predictive Value of 1-Week Postoperative Ultrasonography Findings for the Patency Rate of Arteriovenous Fistula. Kidney Int Rep. 5(10):1746-1752, 2020 77.Nakayama M, Hamada C, Yokoyama K, Tanno Y, Matsuo N, Nakata J, Ishibashi Y, Okuzawa A, Sakamoto K, Nara T, Kakuta T, Nangaku M, Yokoo T, Suzuki Y, Miyata T: A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity. Sci Rep. 10(1):17565, 2020 78.Yang SR, Hua KF, Takahata A, Wu CY, Hsieh CY, Chiu HW, Chen CH, Mukhopadhyay D, Suzuki Y, Ka SM, Huang HS, Chen A: LCC18, a benzamide-linked small molecule, ameliorates IgA nephropathy in mice. J Pathol. 253(4):424-441, 2020 79.Gohda T, Kamei N, Kubota M, Tanaka K, Yamashita Y, Sakuma H, Kishida C, Adachi E, Koshida T, Murakoshi M, Hagiwara S, Funabiki K, Ueda S, Suzuki Y: Fractional excretion of TNF receptor 1 and 2 in patients with type 2 diabetes and normal renal function. J Diabetes Investig. 12(3):382-389, 2021 80.Nihei Y, Nagasawa H, Fukao Y, Kihara M, Ueda S, Gohda T, Suzuki Y: Continuous extracorporeal treatments in a dialysis patient with COVID-19. CEN Case Rep. 10(2):172-177, 2021 81.Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N, Huang ZQ, Knoppova B, Khan A, Hall S, Yanagawa H, Brown R, Winstead CJ, O'Quinn DB, Weinmann A, Gharavi AG, Kiryluk K, Julian BA, Weaver CT, Suzuki Y, Novak J: Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J Autoimmun. 118:102593，2021 82.Han W, Suzuki T, Watanabe S, Nakata M, Ichikawa D, Koike J, Oda T, Suzuki H, Suzuki Y, Shibagaki Y: Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis. Medicine (Baltimore). 5;100(5):e24460, 2021 83.Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, Matsuzaki K, Suzuki Y, Katafuchi R, Reich HN, Cattran D, International IgA Nephropathy Network: Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. J Am Soc Nephrol. 32(2)436-447, 2021 84.Matsuzaki K, Suzuki H, Kawamura T, Tomino Y, Suzuki Y: Utility of remission criteria for the renal prognosis of IgA nephropathy. Clin Exp Nephrol. in press 85.Kano T, Suzuki H, Makita Y, Fukao Y, Suzuki Y: Nasel-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. Kidney Int. 5: S0085-2538(21)00467-1, 2021 86.Yang SR, Hua KF, Takahata A, Wu CY, Hsieh CY, Chiu HW, Chen CH,　Mukhopadhyay D, Suzuki Y, Ka SM, Huang HS, Chen A: LCC18, a benzamide-linked small molecule, ameliorates IgA nephropathy in mice. J Pathol. 253:427-441, 2021 87.Gohda T, Yanagisawa N, Murakoshi M, Ueda S, Nishizaki Y, Nojiri S, Ohashi Y, Ohno I, Shibagaki Y, Imai N, Iimuro S, Kuwabara M, Hayakawa H, Kimura K, Hosoya T, Suzuki Y: Association between kidney function decline and baseline TNFR levels or change ratio in TNFR by febuxostat chiefly in non-diabetic CKD patients with asymptomatic hyperuricemia. Front Med. 8:634932, 2021 88.Nagasawa H, Ueda S, Otsuka T, Kaifu K, Ono S, Okuma T, Kobayashi T, Matsushita S, Kasai T, Dohi T, Fukushima Y, Amano A, Suzuki Y: Safety and efficacy of using cereal food　(Frugra®) to improve blood pressure and bowel health in patients undergoing chronic hemodialysis: A pilot study. J Pharmacol Sci. 147:132-137, 2021 89.Fukao Y, Nagasawa H, Nihei Y, Hiki M, Naito T, Kihara M, Gohda T, Ueda S, Suzuki Y: COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine. Clin Exp Nephrol. 25:1240-1246, 2021 90.Akira M, Suzuki H, Ikeda A, Iwasaki M, Honda D, Takahara H, Rinnno H, Tomita S, Suzuki Y: Atypical histological abnormalities in an adult patient with nephronophthisis harboring NPHP1 deletion. BMC Nephrol. 22:261, 2021 91.Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejia-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JSF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J: Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 100:753-779, 2021 92.Suzuki H, Kikuchi M, Koike K, Komatsu H, Matsuzaki K, Takahashi K, Ichikawa D, Okabe M, Obata Y, Katafuchi R, Kihara M, Kohatsu K, Sasaki T, Shimizu A, Nakanishi K, Fukuda A, Miyazaki Y, Muto M, Yanagawa H, Suzuki Y, Fujimoto S, Furuichi K, Okada H, Narita I: A digest from evidence-based clinical practice guideline for IgA nephropathy 2020. Clin Exp Nephrol. 25:1269-1276, 2021 93.Murakoshi M, Gohda T, Adachi E, Ichikawa S, Hagiwara S, Suzuki Y: Differential organ-specific inflammatory response to progranulin in high-fat diet-fed mice. Sci Rep. 11:1194, 2021 94.Usui N, Yokoyama M, Nakata J, Suzuki Y, Tsubaki A, Kojima S, Inatsu A, Hisadome H, Uehata A: Association between social frailty as well as early physical dysfunction and exercise intolerance among older patients receiving hemodialysis. Geriatr Gerontol Int. 21:664-669, 2021 95.Ueno Y, Saito A, Nakata J, Kamagata K, Taniguchi D, Motoi Y, Io H, Andica C, Shindo A, Shiina K, Miyamoto N, Yamashiro K, Urabe T, Suzuki Y, Aoki S, Hattori N: Possible Neuroprotective Effects of l-Carnitine on White-Matter Microstructural Damage and Cognitive Decline in Hemodialysis Patients. Nutrients. 13:1292, 2021 96.Fukuzaki H, Nakata J, Shirotani Y, Shimizu Y, Maiguma M, Nohara N, Suzuki Y: An Unusual Case of Recurrent Migration of the Peritoneal Dialysis Catheter into the Inguinal Hernia Sac. Case Rep Nephrol Dial. 11:152-157, 2021 97.Shimizu Y, Wakabayashi K, Iwasaki H, Kishida C, Seki S, Okuma T, Iwakami N, Iwasawa T, Maekawa H, Tomino Y, Wada R, Suzuki Y: Immunotactoid Glomerulopathy with Nontuberculous Mycobacterial Infection: A Novel Association. Case Rep Nephrol Dial. 11:136-146, 2021 98.Zambrano S, He L, Kano T, Sun Y, Charrin E, Lal M, Betsholtz C, Suzuki Y, Patrakka J: Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing. Kidney Int. 101(4):752-765, 2022 99.Fukuzaki H, Nakata J, Nojiri S, Shimizu Y, Kano T, Shirotani Y, Maeda T, Nohara N, Io H, Suzuki Y: Negative-pressure wound therapy is effective for peritoneal dialysis catheter exit-site management in the early postoperative period. Sci Rep. 12(1):70, 2022 100.Matsuzaki K, Aoki R, Nihei Y, Suzuki H, Kihara M, Yokoo T, Kashihara N, Narita I, Suzuki Y: Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 26(4): 316-322, 2022 101.Ishida M, Matsuzaki K, Ikai H, Suzuki H, Kawamura T, Suzuki Y: Cost analysis of screening for IgA nephropathy using novel biomarkers. Value Health Reg Issues. 29:8-15, 2022 102.Usui N, Uehata A, Nakata J, Inatsu A, Tsubaki A, Saitoh M, Izumi T, Chiba Y, Kojima S, Suzuki Y: Effect of blood volume change related to intensity of intradialytic aerobic exercise on hemodialysis adequacy: a pilot study. Int Urol Nephrol. 54(6): 1427-1434, 2022 103.Barratt J, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, Jin H, Gühring H, Appel G, on behalf the JANUS study investigators: Atacicept in patients with immunoglobulin A nephropathy and persistent proteinuria: results of the randomized, double-blind, placebo-controlled Phase Ⅱ JANUS study. Kidney Int Rep. 7(8):1831-1841, 2022 104.Barratt B, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, Jin H, Gühring H, Appel G, JANUS study investigators: Randomized Phase II JANUS Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Kidney Int. 7:1831-1841, 2022 105.Joh K, Nakazato T, Hashiguchi A, Shimizu A, Katafuchi R, Okonogi H, Koike K, Hirano K, Tsuboi N, Kawamura T, Yokoo T, Narita I, Suzuki Y: Structural modeling for Oxford histological classifications of immunoglobulin A nephropathy. PLoS One. 17(9): e0268731, 2022 106.Murakoshi M, Gohda T, Sakuma H, Shibata T, Adachi E, Kishida C, Ichikawa S, Koshida T, Kamei N, Suzuki Y: Progranulin and Its Receptor Predict Kidney Function Decline in Patients with Type 2 Diabetes. Front Endocrinol (Lausanne). 13:849457, 2022 和文原著 1.富野康日己、淺沼克彦、井尾浩章、鈴木　仁、田中裕一、中田純一郎、小林則善、武田之彦、稲見裕子、清水芳男、柘植俊直、鈴木祐介、大澤　勲、来栖　厚、濱田千江子、堀越　哲、若林道郎、青木竜弥、金口泰彦、彰　一祐：高カリウム血症を伴う慢性腎臓病（ＣＫD）患者に対するポリスチレンスルホン酸カルシウムゼリーの長期投与効果の検討Ther. Res. 31:1471-1480, 2010 2.高良勝彦、鈴木　仁、鈴木祐介、堀越哲、富野康日己：慢性腎臓病を伴う高血圧患者に対する塩酸ベニジピンの尿蛋白改善効果作用並びに抗酸化作用 –未治療高血圧患者における層別解析研究- 順天堂医学57: 610-616, 2011 3.佐々木洋平、大澤　勲、中田純一郎、小林則善、荻島達也、藤目　真、伊藤浩一、荒川　　敦、八尾隆史、鈴木祐介、来栖　厚、堀越　哲、富野康日己：頭痛と低カルシウム血症を呈した原発性アルドステロン症に対して病側副腎摘除術を施行した１症例順天堂医学 57: 644-649, 2011 4.松尾清一、川村哲也、鈴木祐介ら　厚生労働科学研究費補助金難治性疾患克服研究事業　進行性腎障害に関する調査研究班報告IgA腎症分科会：IgA腎症の寛解基準の提唱　日腎会誌　55(7)、2013 5.村越真紀、苑田祐二、丸山俊太郎、鈴木仁、鈴木祐介、堀越哲、合田朋仁：　高血圧患者におけるテルミサルタンが炎症・腎機能マーカーに与える影響　　血圧　23: 56-60, 2016 6.濱田千江子、野原奈緒、中田純一郎、町田修一、中潟崇、内藤久士、鈴木祐介 : リストバンド型加速度センサー付ライフログレコーダを使った透析患者の身体活動の評価. 日本透析医会雑誌. 33(1) : 157-162, 2018 7.井尾浩章、中田純一郎、青山留未、井下博之、中野貴則、石坂匡則、福井光峰、富野康日己、鈴木祐介：血液透析患者の内シャント狭窄予防における遠赤外線照射治療の有用性　日本透析医会雑誌　33（2）：321-324，2018 8.神田怜生、井尾浩章、中田純一郎、富野康日己、鈴木祐介：腹膜透析患者における腹膜障害と心血管病イベント発症予測因子としての新規マーカー：Pentraxin3（PTX3）に関する研究　日本透析医会雑誌　36: 135-140, 2021 英文総説 1.Tomino Y, Suzuki Y, Tsuge T, Ohmuro H, Suzuki S, Fukui M, Shirato I: IgA nephropathy pathogenesis and treatment. J Nephrol Dial Transplant 6: 518-524, 1997 2.Ruiz-Ortega M, Lorenzo O, Suzuki Y, Gatica A, and Egido J: Role of the renin-angiotensin system in the progression of renal disease. Nephrologia 1: 50, 2000 3.Egido J, Hernandez-Presa MA, Tunon J, Blanco-Colio LM, Ortego M, Suzuki Y, Plaza JJ, Guijarro C: Transcriptional factor kB (NF-kB) and cardiovascular disease. Cardiovascular risk factors 9: 159-168, 2000 4.Suzuki Y, Ruiz-Ortega M, Egido J: Angiotensin II: a double-edged sword in inflammation. J Nephrol. Suppl 3: S101-110, 2000 5.Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, and Egido J: Proinflammatory actions of Angiotensin II. Current Opin of Hypertension and Renal Disease 10: 321-329, 2001 6.Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J: Role of the Renin-Angiotensin system in vascular diseases: expanding the field. Hypertension 38: 1382-1387, 2001 7.Gomez-Guerrero C, Suzuki Y, Egido J: Identification of IgA receptors in human mesangial cells. In the search for “El Dorado”. Kidney Int 62: 715-717, 2002 8.Ruiz-Ortega M, Alcazar R, Ruperez M, Suzuki Y, Esteban V, Rodriguez-Vita J, sanchez-Lopez E, Egido J: Inflamacion y angiotensin II en la fisiopatologia del dano vascular diabetico. Med Clin 118: 1-12, 2002 9.Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Estevan V, Egido J: Inflammation and angiotensin II. Int Biochem Cell Biol 35: 881-900, 2003 10.Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, Tomino Y and Egido J: Angiotensin II and renal diseases: what is the involvement of the immune system? Nephrol Dial Transpant 18: 1423-1426, 2003 11.Caramelo C, Alvarez-Arroyo MV, Yague S, Suzuki Y, Castilla MA, Velasco L, Gonzalez-Pacheco FR, Tejedor A: Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward. Nephrol Dial Transpant 19: 285-288, 2004 12.Tomino Y, Tsuge T, Suzuki Y, Gu L, Tanimoto M, Gohda T, Horikoshi S: Basic research in progressive glomerulopathies: The role of fibrosing factors in IgA nephropathy and diabetic nephropathy. Kidney Int 94: s92-95, 2005 13.Suzuki Y, Tomino Y: Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: insights from animal models. Semin Nephrol 28: 66-77, 2008 14.Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, Tomino Y: Pathological role of tonsillar B cells in IgA nephropathy. Clin Dev Immunol:　639074, 2011 15.Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Mestecky J, Suzuki H: Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol 72: 60-63, 2011 16.Suzuki Y, Suzuki H, Sato D, Kajiyama T, Okazaki K, Hashimoto A, Kihara M, Yamaji K, Satake K, Nakata J, Aizawa M, Novak J, Tomino Y: Reevaluation of the mucosa-bone marrow axis in IgA nephropathy with animal models. Adv Otorhinolaryngol 72: 64-67, 2011 17.Suzuki Y, Suzuki H, Makita Y, Takahata A, Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H, Okazaki K, Tomino Y: Diagnosis and activity assessment of IgA nephropathy: current perspectives on non-invasive testing with aberrantly glycosylated IgA-related biomarkers. Int J Nephrol and Renovasc Dis 7: 409-414, 2014 18.Suzuki H, Suzuki Y, Novak J, Tomino Y: Development of Animal Models of Human IgA Nephropathy. Drug Discov Today Dis Models 11: 5-11, 2014 19.Suzuki Y, Suzuki H, Yasutake J, Tomino Y: Paradigm shift in activity assessment of IgA nephropathy–optimizing the next generation of diagnostic and therapeutic maneuvers via glycan-targeting. Expert Opin Biol Ther 20: 1-11, 2015. 20.Hagiwara　S, Gohda T, Funabiki K, Suzuki Y: Essential points of treatment and examination to prevent diabetic kidney disease aggravation. Juntendo Medical Journal. 65(6):529-536,2019 21.Okonogi H, Kawamura T, Joh K, Koike K, Miyazaki Y, Ogura M, Tsuboi N, Hirano K, Matsushima M, Yokoo T, Horikoshi S, Suzuki Y, Yasuda T, Shirai S, Shibata T, Hattori M, Akioka Y, Katafuchi R, Hashiguchi A, Hisano S, Shimizu A, Kimura K, Maruyama S1, Matsuo S, Tomino Y; Special IgA Nephropathy Study Group.: A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clin Exp Nephrol 23(1):16-25, 2019 22.Murakoshi M, Gohda T, Suzuki Y: Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease. Int J Mol Sci. 21:1957, 2020 23.Kobayashi T, Ueda S, Takagi M, Kihara M, Suzuki Y: Pathophysiological roles of ADMAmediated endothelial injury in hypertensive disorders of pregnancy. Hypertens Res Pregnancy. 8:40-46, 2020 24.Yap DYH, McMahon LP, Hao CM, Hu N, Okada H, Suzuki Y, Kim SG, Lim SK,　Vareesangthip K, Hung CC, Nangaku M, APSN HIF-PHI Recommendation Committee: Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors. Nephrology (Carlton). 26(2):105-118, 2020 25.Sakuma H, Hagiwara S, Kantharidis P, Gohda T, Suzuki Y: Potential Targeting of Ranal Fibrosis in Diabetic Kidney Disease Using MicroRNAs. Front Pharmacol. 11:587689, 2020 26.Suzuki Y, Monteiro RC, Coppo R, Suzuki H: The phenotypic of IgA nephropathy and its race- and gender-dependent molecular mechanisms. Kidney 360. 2:1339-1348, 2021 27.Monteiro RC, Suzuki Y: Are there animal models of IgA nephropathy? Semin Immunopathol. 43:639-648, 2021 28.Salsabila SA, Rosyid AN, Empitu MA, Kadariswantiningsih IN, Suryantoro SD, Haryati MR, Thaha M, Suzuki Y: Kidney-pulmonary Crosstalk from A Pathophysiological Perspective. J. Respi. 8:44-51, 2022 総説 1.鈴木祐介、富野康日己：貧血管理、至適Hb値と鉄剤の功罪　内科 104:61-65, 2009 2.鈴木祐介、富野康日己：　糸球体腎炎（IgA腎症を含む）内科疾患の診断基準・病型分類・重症度　内科　105:1091-1095, 2010 3.鈴木祐介、富野康日己：CKDの診断　尿検査　腎と透析 69（増刊号）:41-44, 2010 4.鈴木祐介：ONTARGET試験への評価・コメント　Nephrology Frontier 9:72, 2010 5.鈴木祐介、鈴木仁、佐藤大介、梶山忠弘、渡辺智成、富野康日己：IgA腎症とSchoenlein Henoch紫斑病　腎と透析　70:73-76, 2010 6.鈴木祐介、富野康日己：　結節性多発動脈炎　医学と薬学65:313-317, 2011 7.鈴木祐介：IgA腎症に関する臨床上の問題点―成因からみた治療の体系化―　炎症と免疫 19:111-115, 2011 8.鈴木祐介：くるみ割り人形症候群　「知っておきたい内科症候群」内科　109:1407-1410, 2012 9.川村哲也、鈴木祐介：CKD関連ガイドラインを臨床に活かす　IgA腎症　Nephrology Frontier 11: 2012 (in press) 10.鈴木祐介：IgA腎症のバイオマーカーと治療戦略　―根治治療開発のための条件― 医薬ジャーナル 2012 (in press) 11.鈴木仁、鈴木祐介、富野康日己：IgA腎症患者扁桃とTLR　Annual Review2013 腎臓:47-56, 2013 12.鈴木祐介、富野康日己：IgA腎症とステロイド療法　臨床と研究　90 (7), 2013 13.鈴木祐介、富野康日己：IgA腎症のステロイド療法のUp to date　カレントテラピー　31 (6), 2013 14.鈴木祐介：学会レポート　第58回日本透析医学会学術集会・総会　腎・高血圧の最新治療　2013 15.鈴木祐介、富野康日己：IgA腎症の病態における扁桃B細胞の役割　「今明らかにされた扁桃とIgA腎症を結びつけるエビデンス：腎臓内科学、病理学、耳鼻咽喉科学のアプローチから」　口腔・咽頭科　2013　 16.鈴木祐介、鈴木仁、柳川宏之、松崎慶一、牧田郁子、高畑曉子、富野康日己：IgA腎症の新しいバイオマーカー　腎と透析：76; 31-35, 2014 17.鈴木祐介、富野康日己：特集　腎臓学この一年の進歩2013：腎炎・ネフローゼ症候群」　日本腎臓学会誌: 56:14-21, 2014 18.鈴木仁、鈴木祐介：「IgA腎症早期発見のための新規バイオマーカーを用いた血尿の２次スクリーニングの試み」腎・高血圧の最新治療　2015 19.高畑曉子、鈴木祐介：IgA腎症における性差ー性ホルモンの関与―　腎臓内科・泌尿器科　1:485-490, 2015 20.鈴木仁、木原正夫、鈴木祐介: IgA腎症とIgA血管炎の共通病態東京内科医会会誌 33:169-170, 2017 21.鈴木祐介：【糸球体腎炎】粘膜免疫異常とIgA腎症　日本腎臓学会誌　58:648-655, 2016 22.鈴木仁、木原正夫、鈴木祐介: IgA腎症とIgA血管炎の共通病態東京内科医会会誌 33:169-170, 2017 23.狩野俊樹、鈴木仁、鈴木祐介：【腸管細菌叢と腎疾患】腸管粘膜免疫異常と腸腎関連　日本腎臓学会会誌　59:552-556，2017 24.木原正夫、鈴木祐介：IgA腎症治療の国際比較. 腎臓内科・泌尿器科. 7:84-88, 2018 25.狩野俊樹、鈴木祐介：【腎疾患診療の未来　最新知見のエッセンシャル: 腎疾患の疫学・病因の研究の進歩】IgA腎症の発症機構. 診断と治療. 106:423-428, 2018 26.日高輝夫、鈴木祐介：【疾患・病態を理解する-尿沈渣レファレンスブック：腎疾患-症候群と尿沈渣成分】ネフローゼ症候群. 臨床検査. 62:462-463, 2018 27.井尾浩章、野原奈緒、井下博之、中野貴則、石坂匡則、鈴木祐介：早期慢性腎臓病(CKD stage 1-3)患者の透析導入に関連する因子の検討練馬医学会誌　24:84–87,2018 28.出崎雄也、鈴木祐介：【腎と透析ベッドサイド検査事典】 (第11章)免疫血清学的検査　免疫グロブリン　クリオグロブリン定性　腎と透析増刊号84:338-340,2018 29.鈴木仁、鈴木祐介：【血管炎とアレルギー疾患 -内因性・外因性アジュバントの関わり-】 Tonsil induced autoimmune/inflammatory syndrome(TIAS)としてのIgA腎症　アレルギー・免疫　25：802‐809,2018 30.井尾浩章、若林啓一、神田怜生、中田純一郎、井下博之、中野貴則、石坂匡則、鈴木祐介：HD導入時のシャント管理　心機能とシャント血流を評価する　腎と透析別冊腎不全外科2018　84：59-62, 2018 31.二瓶義人、鈴木祐介：【特殊：腎臓病のエンドポイント】IgA　腎症の病態から考えるエンドポイント　The endpoint based on the pathogenesis of IgA nephropathy　日本腎臓学会誌　60：592-596, 2018 32.禾千絵子、鈴木祐介：【血管炎(第2版)-基礎と臨床のクロストーク-】小型血管炎　IgA血管炎　疫学・病態　日本臨床　76：388-392, 2018 33.鈴木仁、鈴木祐介：Gd-IgA1(糖鎖異常IgA1)モノクローナル抗体　腎・高血圧の最新治療　7：144-147, 2018 34.禾千絵子、鈴木仁、鈴木祐介：IgA腎症の発症機序から考える治療の妥当性　IgA腎症の臨床　Clinical medicine of IgA nephropathy　2-7, 2018 35.鈴木仁、鈴木祐介：IgA腎症の新規分子標的薬の可能性　IgA腎症の臨床　Clinical medicine of IgA nephropathy　187-189, 2018 36.鈴木仁、鈴木祐介: Tonsil indeuced autoimmune/　inflammatorysyndrome(TIAS)としてのIgA腎症. ｱﾚﾙｷﾞｰ・免疫　Allergology & Immunology Vol.25 No.6. 25(6): 76-83, 2018 37.狩野俊樹、鈴木祐介：【腸内細菌叢と腎泌尿器疾患】腎におよぼす腸管免疫の作用　腎臓内科・泌尿器科　7：533-538，2018 38.狩野俊樹、鈴木祐介：扁桃活性化機序からみたIgA腎症　医学のあゆみ　267：236-238，2018 39.佐藤大介、鈴木祐介：【CKD(慢性腎臓病)慢性腎臓病のこれまと今後：最新の実地診療のポイントの整理と活用】IgA腎症の診断と治療 Medical Practice 35 （10）：1547-1552,2018 40.合田朋仁、鈴木祐介: 【糖尿病性腎症と糖尿病性腎臓病:最近の進歩】酸化ストレスをターゲットとした治療：バルドキソロンメチルへの期待月間糖尿病月間糖尿病 10 (8)：86-93,2018 41.小林敬、鈴木祐介: 【特集：臨床検査と総合健診】慢性腎臓病治療における健康診断の重要性総合健診日本総合健診医学会誌 46（2）：22-23,2019 42.中田純一郎、鈴木祐介: IgA腎症 -根治治療開発に求められること腎・高血圧の最新治療 8(2)：68-73,2019 43.木原正夫、鈴木祐介：【特集：IgA腎症-診断・治療の最新動向-】 IgA腎症診療の現況と展望　日本臨床　77（4）：588-592,2019 44.狩野俊樹、鈴木祐介：【特集：IgA腎症-診断・治療の最新動向-】 IgA腎症の病因・病態生理　IgA腎症と粘膜免疫　日本臨床　77（4）：620-624,019 45.牧田侑子、鈴木祐介：【特集：腎疾患の重症化予防-現状と将来】IgA腎症重症化予防-現状と将来　医学と薬学　76（7）：975-979,2019 46.鈴木仁、鈴木祐介：【特集：今、糸球体疾患を考える】一次性糸球体疾患　IgA腎症：新規バイオマーカーを用いた早期診断と活動性評価　腎と透析　86（5）：531-534,2019 47.深尾勇輔、鈴木祐介：【特集：今、糸球体疾患を考える】一次性糸球体疾患　IgA腎症：病因としての粘膜関連リンパ組織　腎と透析　86（5）：527-530,2019 48.塩田遼太郎、鈴木祐介：【第1章　膠原病、血管炎、自己免疫疾患】IgA血管炎・腎臓専門医の視点より　腎と透析　86：109-112,2019 49.牧田侑子、鈴木祐介：【解説】BAFF/APRIL　腎臓内科　11（1）：78-83,2020 50.足立恵理、村越真紀、合田朋仁、鈴木祐介：新規DKD治療薬としてのASK1阻害薬（Selonsertib）への期待　Pharma Medica　 38：63-67,2020 51.毎熊政行、鈴木祐介：IgA腎症の新展開　腎臓内科　12（4）：1-6,2020 52.大塚智之、上田誠二、鈴木祐介：【特集：糖脂質代謝連関と老年病】1.ADMAと心腎連関　The　Lipid　 31（2）：14-20,2020 53.中山麻衣子、鈴木祐介：IgA腎症　生体の科学　71(5)： 2-3,2020 54.鈴木仁、鈴木祐介：腎臓病学この1年の進歩　IgA腎症の病態　日本腎臓学会誌　62: 26-33,2020 55.長澤肇、上田誠二、鈴木祐介：腎臓病　CURRENT THERAPY　39: 53-57, 2021 56.小林敬、鈴木祐介: 糸球体疾患　指定難病としてのIgA腎症の現状と病態腎と透析 91: 55-59, 2021 57.大塚智之、上田誠二、鈴木祐介: 腎臓専門医への紹介のタイミング内科 128: 971-973, 2021 43. 鈴木祐介、二瓶義人、鈴木仁: 医学と医療の最前線　IgA腎症の最新治療とその背景日本内科学会雑誌 110: 2286-2292, 2021 58.佐藤浩司、上田誠二、鈴木祐介：職場高血圧　臨床栄養　138(3):　373-377, 2021 59.毎熊政行、鈴木祐介: IgA腎症　日本臨牀　79:　1873-1879, 2021 英文著書 1.Suzuki Y, Tomino Y: Experimental model of IgA nephropathy. Monograph on IgA nephropathy. London, 2008 2.Suzuki Y. Coppo R, Tomino Y: Beyond the differences in tonsillectomy in IgA nephropathy: from rationale to indications in patients. Pathogenesis and treatment in IgA nephropathy. Tomino Y(Ed), Springer, Tokyo, Japan, 2016 和文著書 1.鈴木祐介:「慢性腎炎症候群（無症候性蛋白尿・血尿を含む）」　今日の治療指針2010年版　山口徹、北原光男、福井次矢（編）、医学書院、東京、2010 2.鈴木祐介:「 IgA腎症に対する扁桃摘出術のEBMとは？　腎臓内科の立場から」　EBM 耳鼻咽喉科・頭頸部腫瘍の治療　2010-2011　池田勝久、武田憲明、原渕保明、丹生健一（編）、中外医学社、東京、2010 3.富野康日己、鈴木祐介、鈴木仁：「IgA腎症の病因に関わるMucosa-Bone Marrow Axisの異常」　臨床粘膜免疫学　清野宏(編)、シナジー、東京、2011 4.鈴木祐介:「蛋白尿を抑制・減少させる薬剤はないのですか？」　生活習慣病・腎臓病・高血圧対策Q&A―みなさんの質問にお答えします　富野康日己（編）、中外医学社、東京、2011 5.鈴木祐介: 「ネフローゼ症候群ってどういう病気ですか？」　生活習慣病・腎臓病・高血圧対策Q&A―みなさんの質問にお答えします　富野康日己（編）、中外医学社、東京、2011 6.鈴木祐介: 「健康診断で毎回尿潜血反応陽性で、遊走腎といわれました。この先、腎機能が低下する可能性はありますか？」　生活習慣病・腎臓病・高血圧対策Q&A―みなさんの質問にお答えします　富野康日己（編）、中外医学社、東京、2011 7.鈴木祐介: 「IgA腎症の発症・進展メカニズム　IgA腎症の発症機序」IgA腎症診療マニュアル　第３版　富野康日己（編）、南江堂、東京、2011 8.鈴木祐介:「アデノシンジアミナーゼ」　臨床検査基準値express　富野康日己（編）、中外医学社、東京、2011 9.鈴木祐介:「イソクエン酸脱水素酵素」　臨床検査基準値express　富野康日己（編）、中外医学社、東京、2011 10.鈴木祐介:「グアナーゼ」　臨床検査基準値express　富野康日己（編）、中外医学社、東京、2011 11.鈴木祐介:「LCAT」　臨床検査基準値express　富野康日己（編）、中外医学社、東京、2011 12.鈴木祐介:「血中、尿アミラーゼ、アイソザイム」　臨床検査基準値express　　富野康日己（編）、中外医学社、東京、2011 13.鈴木祐介:「IgA腎症の発症、進展機序の理解はどこまで進んだのでしょうか？」　EBM腎臓病学の治療2011-2012　柏原直樹、南学正臣（編）、中外医学社、2011 14.鈴木祐介:「IgA腎症の発症には何らかのアレルギー素因が関与するのでしょうか？」　IgA腎症診療指針Q&A 富野康日己、川村哲也（編）松尾清一（監修）、診断と治療社、東京、 2011 15.鈴木祐介:「IgA腎症の進展機序のうち、免疫学的機序について教えてください」　IgA腎症診療指針Q&A 富野康日己、川村哲也（編）松尾清一（監修）、診断と治療社、東京、2011 16.鈴木祐介:「IgA腎症発症の地域差と腎生検の時期」　IgA腎症診療指針Q&A 富野康日己、川村哲也（編）松尾清一（監修）、診断と治療社、東京、2011 17.鈴木祐介:「IgA腎症とはどういう疾患ですか？」　CKD診療連携―Evidence & Tips―　富野康日己（編）、中外医学社、東京、2012 18.鈴木祐介:「IgA腎症での扁桃摘出術とステロイドパルス併用療法とは何ですか？」　CKD診療連携―Evidence & Tips―　富野康日己（編）、中外医学社、東京、2012 19.鈴木祐介:「透析の医療保険はどうなっていますか？」　ナーシングケアQ&A　富野康日己（編）、総合医学社、東京、2012 20.鈴木祐介：「脂質異常症（高脂血症）が腎臓病・血圧に悪い理由は何ですか？」　腎臓病・高血圧と薬剤　実践Q&A、富野康日己（編）、中外医学社、東京、　2013 21.鈴木祐介：「高尿酸血症は、どうして腎臓に悪いのですか？腎臓が悪いから高尿酸血症になるのですか？」　腎臓病・高血圧と薬剤　実践Q&A　富野康日己（編）、中外医学社、東京、2013 22.鈴木祐介：「高尿酸血症は、どうして腎臓に悪いのですか？腎臓が悪いから高尿酸血症になるのですか？」　腎臓病・高血圧と薬剤　実践Q&A、富野康日己（編）、中外医学社、東京、2013 23.鈴木祐介：「低尿酸血症は、どうして腎臓に悪いのですか？」　腎臓病・高血圧と薬剤　実践Q&A　富野康日己（編）、中外医学社、東京、2013 24.鈴木祐介、増田稔：「有病者の栄養管理　慢性腎臓病（ＣＫＤ）ネフローゼ症候群」　スマート栄養管理術１００－栄養管理が重要であるこれだけの理由　富野康日己（編）、医歯薬出版、東京、2014 25.鈴木祐介、増田稔：「有病者の栄養管理　慢性腎臓病（ＣＫＤ）ネフローゼ症候群」　スマート栄養管理術１００－栄養管理が重要であるこれだけの理由　富野康日己（編）、医歯薬出版、東京、2014 26.鈴木祐介：「IgA腎症、紫斑病性腎炎」　今日の治療指針2015　福井次矢、高木誠、小室一誠（編）、医学書院、東京、2014 27.鈴木祐介：「4)IgA腎症」　Newエッセンシャル　富野康日己（編）、腎臓内科学、医歯薬出版、東京、134-146　2015 28.鈴木祐介：井尾浩章：「III．症候・病態編　排尿痛」、内科診断学　第３版　福井次矢、奈良信雄（編）、医学書院、東京、617-621　2016 29.鈴木祐介：「②血尿」　内科外来診断NAVI 2016、中外医学社、東京 30.高橋敬子、鈴木祐介：「6.IgA腎症（成人）：ステロイド療法の適応と実際」腎疾患・透析　最新の治療　2017-2019、山縣邦弘、南学正臣（編）、南江堂、東京、2017 31.佐藤大介、鈴木祐介: 【CKD(慢性腎臓病)慢性腎臓病のこれまでと今後：最新の実地診療のポイントの整理と活用】IgA腎症の診断と治療、Medical Practice、文光堂、東京、l35（10）：1547-1552,2018 32.長澤肇、上田誠二、鈴木祐介：「10.ADMA,SDMA」、透析患者の検査値の読み方、深川雅史（監修）、日本メディカルセンター、4：254-255,2018 33.禾千絵子、鈴木仁、鈴木祐介：IgA腎症の発症機序から考える治療の妥当性　IgA腎症の臨床、Clinical medicine of IgA nephropathy、2-7, 2018. 34.鈴木仁、鈴木祐介：IgA腎症の新規分子標的薬の可能性　IgA腎症の臨床 Clinical medicine of IgA nephropathy　187-189, 2018 35.鈴木祐介: 【8章腎・泌尿器疾患】2.　慢性糸球体腎炎今日の処方　改訂第6版南江堂 328-329,2019 36.長澤肇、上田誠二、鈴木祐介: 【5章　血液生化学（代謝、内分泌）】　10.ADMA、SDMA 透析患者の検査値の読み方　第4版日本メディカルセンター 254-255,2019 37.木原正夫、鈴木祐介：【B.糸球体疾患】10.IgA腎症およびIgA血管炎（Henoch-Schoenlein purpura紫班病）、プロフェッショナル腎臓病学、南学正臣（編著）、中外医学社、183-194, 2020 38.小林敬、鈴木祐介：腎機能悪化の危険性が高いのはどのような患者ですか？、　わかる！できる！腎臓リハビリテーション　Q＆A、医歯学出版㈱、36-37, 2021 39.小林敬、鈴木祐介：1)IgA腎症　IgA腎症の診断や活動性評価はどのように行いますか？、腎臓病診療Q＆A AKI～CKD～腎難病まで、山縣邦弘（監修）、東京医学社、182-183、2021

研究テーマ

腎臓内科

研究業績（論文）

英文原著

1.Suzuki Y, Takeda Y, Sato D, Kanaguchi Y, Tanaka Y, Kobayashi S, Suzuki K, Hashimoto H, Ozaki S, Horikoshi S, Tomino Y. Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan. Mod Rheumatol. 20:54-62, 2010.

2.Suzuki Y, Kanaguchi Y, Ken Osaki, Takeshi Sugaya, Satoshi Horikoshi, Yasuhiko Tomino. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis. (1st and 2nd authors equally contributed to this paper.) Nephrol Dial Transplant. 26:3465-3473, 2011

3.Tomino Y, Shimizu Y, Hamada C, Kurusu A, Ohsawa I, Suzuki Y, Tsuge T, Ito H, Kobayashi N, Takeda Y, Asanuma K, Tanaka Y, Suzuki H, Nakata J, Takara K, Horikoshi S. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease. J Nephrol 24:756-763, 2011.

4.Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, Tomino Y. Pathological role of tonsillar B cells in IgA nephropathy. Clin Dev Immunol. 2011:639074, 2011.

5.Suzuki Y, Suzuki H, Sato D, Kajiyama T, Okazaki K, Hashimoto A, Kihara M, Yamaji K, Satake K, Nakata J, Aizawa M, Novak J, Tomino Y. Reevaluation of the mucosa-bone marrow axis in IgA nephropathy with animal models. Adv Otorhinolaryngol. 72:64-67, 2011

6.Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, Horikoshi S, Ikeda K, Tomino Y. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant. 27:1090-1097, 2012
2012 (in press)

7.Okazaki K, Suzuki Y, Otsuji M, Suzuki H, Kihara M, Kajiyama T, Hashimoto A, Nishimura H, Brown R, Hall S, Novak J, Izui S, Hirose S, Tomino Y. Establishment of a novel ddY mouse model with early onset IgA nephropathy. J Am Soc Nephrol. 23:1364-1374, 2012

8.Hashimoto A, Suzuki Y, Suzuki H, Ohsawa I, Brown R, Hall S, TanakaY, Novak J, Ohi H, Tomino Y. Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am J Pathol, 181:1338-1347, 2012

9.hi S, Novak J, Tomino Y.Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Horikos Nephrol Dial Transplant. 2012 (in press)

10.Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, Matsuo S, Tomino Y. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. 2013 (in press)

11.Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2013 Aug 4. [Epub ahead of print]

12.Osaki K, Suzuki Y, Sugaya T, Tanifuji C, Nishiyama A, Horikoshi S, Tomino Y. Amelioration of Angiotensin II-Induced Salt-Sensitive Hypertension by Liver-Type Fatty Acid-Binding Protein in Proximal Tubules. Hypertension. 2013 62:712-8. doi: 10.1161/HYPERTENSIONAHA.113.01203, 2013

13.Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y. Serum levels of galactose deficient IgA1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol. 2014 (in press)

14.Suzuki Y, Nakata J, Hitoshi Suzuki, Daisuke Sato, Tatsuya Kano, Hiroyuki Yanagawa, Keiichi Matsuzaki, Satoshi Horikoshi, Jan Novak, Yasuhiko Tomino. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. (1st and 2nd authors equally contributed to this paper.) PLOS ONE 9(2):e89707. doi: 10.1371/journal.pone.0089707. eCollection 2014.

15.Maiguma M, Suzuki Y, Suzuki H, Okazaki K, Aizawa M, Muto M, Tomino Y. Dietary zinc is a key environmental modifier in the progression of IgA nephropathy. PLOS ONE. 9(2):e90558. doi: 10.1371/journal.pone.0090558. eCollection 2014.

16.Aizawa M, Suzuki Y, Suzuki H, Pang H, Kihara M, Nakata J, Yamaji K, Horikoshi S, Tomino Y. Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy. PLOS ONE. 9(4):e95365. doi: 10.1371/journal.pone.0095365. eCollection 2014.

17.Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLOS ONE. 9(5):e98081. doi: 10.1371/journal.pone.0098081. eCollection 2014.

18.Satake K, Shimizu Y, Sasaki Y, Yanagawa H, Suzuki H, Suzuki Y, Horikoshi S, Honda S, Shibuya K, Shibuya A, Tomino Y Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy. BMC Nephrol. 15:89, 2014

19.Suzuki Y, Suzuki H, Makita Y, Takahata A, Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H, Okazaki K, Tomino Y. Diagnosis and activity assessment of IgA nephropathy: current perspectives on non-invasive testing with aberrantly glycosylated IgA-related biomarkers. Int J Nephrol and Renovasc Dis. 2014

20.Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y. The kinetics of glomerular deposition of nephritogenic IgA. PLOS ONE. 2014 19;9(11):e113005. doi: 10.1371/journal.pone.0113005. eCollection 2014.

21.Makita Y, Tanaka Y, Shimizu Y, Takeda Y, Kanamaru Y, Ohsawa I, Suzuki Y, Kurusu A, Horikoshi S, Tomino Y. A case of Fabry disease, in which renal symptoms served as a diagnostic prompt. Juntendo Medical Journal 2014 60: 353-357.

22.Suzuki Y, Suzuki H, Yasutake J, Tomino Y. Paradigm shift in activity assessment of IgA nephropathy–optimizing the next generation of diagnostic and therapeutic maneuvers via glycan-targeting. Expert Opinion on Biological Therapy 2015 20:1-11

23.Suzuki H, Suzuki Y, Novak J, Tomino Y. Development of Animal Models of Human IgA Nephropathy. Drug Discov Today Dis Models. 2014 Spring;11:5-11.

24.Suzuki Y, Yasutake J, Suzuki H, Hiura N, Yanaga Hwa1, Makita Y, Kaneko E, Tomino Y. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA Nephropathy. Nephrol Dial Transplant. 30: 1315-1321,2015 (1st and 2nd authors are equally contributed to this work)

25.Chunbei L, Kanamaru Y, Watanabe T, Tada N, Horikoshi S, Suzuki Y, Zhihong L, Tomino Y: Targeted IgA Fc Receptor I (FcαRI) Therapy in the Early Intervention and Treatment of Pristane Induced Lupus Nephritis in Mice. Clin Exp Immunol.181:407-416, 2015

26.Yang Gyun K, Alvarez M, Suzuki H, Hirose S, Izui S, Tomino Y, Bertrand H, Suzuki Y: Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS One 10:e0137044, 2015

27.Kamijo S, Nunomura S, Ra C, Kanaguchi Y, Suzuki Y, Ogawa H, Okumura K, Takai T: Innate basophil IL-4 responses against allergens, endotoxin, and cytokines require the Fc receptor  -chain. J Allergy Clin Immun, pii: S0091-6749(15)01671-1, 2015

28.Yamanaka T, Tamauchi H, Suzuki Y, Suzuki H, Horikoshi S, Terashima M, Iwabuchi K, Habu S, Okumura K, Tomino Y: Release from Th1-type immune tolerance in spleen and enhanced production of IL-5 in Peyer's patch by cholera toxin B induce the glomerular deposition of IgA.　 Immunobiology, 221:577-85, 2016

29.Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z,Wyatt RJ, Novak J, Julian BA: Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? Dis Markers 2016: 7806438, 2016

30.Suzuki H, Kihara M, Mano S, Kobayashi T, Kanaguchi Y, Hidaka T, Gohda T, Suzuki Y: Efficacy and Safety of Denosumab for the Treatment of Osteoporosis in Patients with Chronic Kidney Disease. Clin Exp Nephrol 2017 (in press)

31.Atikemu K, Suzuki Y, Otsuji M, Horikoshi S, Tomino Y: Influence of Estrogen on the Progression of Kindney Injury in Murine IgA Nephropathy. Juntendo Medical Journal 63: 178-185,2017

32.Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakui S, Righini C, Maiguma M, Izui S, Tomino Y, Huard B, Suzuki Y: Toll-like Receptor 9 Stimulation lnduces Aberrant Expression of a Proliferation-lnducing Ligand by Tonsillar Germinal Center B Cell in IgA Nephropathy. J Am Soc Nephrol 28: 1227-1238, 2017

33.Sasaki Y, Hidaka T, Ueno T, Akiba-Takagi M, Trejo JA, Seki T, Nagai-Hosoe Y, Tanaka E, Horikoshi S, Tomino Y, Suzuki Y, Asanuma K: Sorting Nexin 9 facilitates podocin endocytosis in the injured podocyte. Sci Rep 7: 43921, 2017

34.Hara K, Hamada C, Wakabayashi K, Kanda R, Kaneko K, Horikoshi S, Tomino Y, Suzuki Y: Scavenging of reactive oxygen species by astaxanthin inhibits epithelial-mesenchymal transition in high glucose-stimulated mesothelial cells. Plos One 12: e0184332, 2017

35.Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z, Kiryluk K, Suzuki Y, Wyatt RJ, Tomino Y, Gharavi AG, Weinmann A, Julian BA, Willey CD, Novak J: Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. Kidney Int Rep 2: 1194-1207, 2017

36.Inoue MK,Yamamotoya T, Nakatsu Y, Ueda K,1 Yuki Inoue Y, Matsunaga Y,　Sakoda H, Fujishiro M, Ono H, Morii K, Sasaki K, Masaki T, SuzukiY, Asano T, Kushiyama A: The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. Int J Mol Sci.19(12): 3967-3980, 2018

37.Ohsawa I, Honda D, Hisada A, Inoshita H, Onda-Tsueshita K, Mano S, Sato N, Nakamura Y, Shimizu T, Gotoh H, Goto Y, Suzuki Y, Tomino Y: Clinical Features of Hereditary and Mast Cell-mediated Angioedema Focusing on the Differential Diagnosis in Japanese Patients. Intern Med, 57; 319-324 2018

38.Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamazaki K, Sofue T, Kano T, Suzuki Y: IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1 oriented pathogenesis. Kidney Int, 93: 700-705, 2018

39.Asao R, Seki T, Takagi M, Yamada H, Kodama F, Hosoe-Nagai Y, Tanaka E, Trejo JAO, Yamamoto-Nonaka K, Sasaki Y, Hidaka T, Ueno T, Yanagita M, Suzuki Y, Tomino Y, Asanuma K : Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis. Sci Rep. 8(1):5061, 2018

40.Suzuki Y: B Cells in IgAN and the Rationale for B Cell Directed Therapies in IgAN. Kidney Diseases. 4:145-194, 2018.

41.Io H, Suzuki Y.: Strategy for Prevention of Left Ventricular Remodeling in Predialysis and Dialysis Patients. Contrib Nephrol. 196：13-21, 2018.

42.Thaha M, Empitu MA, Kadariswantiningsih IN, Nugroho CW, Hasanatulidhhiyah N, Rasyid H, EI Hakim Z, Suryansyah MM, Alda RR, Alsagaff MY, Amin M, Santoso D, Suzuki Y.: Anthropometry-based Body Fat Percentage Predicts High hs-CRP in Chronic Kidney Disease Patients. Indones Biomed J. 10(2):184-191, 2018.

43.Sato D, Gohda T, Kihara M, Kanaguchi Y, Kobayashi T, Mano S, Sasaki Y, Nohara N, Murakoshi M, Nakata J, Suzuki H, Ueda S, Horikoshi S, Suzuki Y.: Effect of Zinc Acetate Dihydrate (Nobelzin®) Tretement on Anemia and Taste Disorders in Patients with Chronic Kidney Disease with　Hypozincemia. Acta Medica Okayama. 72;（5）: 535-538, 2018.

44.Suzuki H, Suzuki Y.: Murine Models of Human IgA Nephropathy. Semin Nephrol. 38 (5): 513 – 520, 2018.

45.Takahashi K, Ueda K, Kobayashi T, Nishiyama A, Fujisawa T, Sugaya T, Shiota S, Takahashi K, Gohda T, Horikoshi S, Suzuki Y. Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease. Sci Rep. 8(1):17926, 2018.

46.Yamasaki K, Suzuki H, Yasutake J, Yamasaki Y, Suzuki Y. Galactose-Deficient IgA1-Specific Antibody Recognizes GalNAc-Modified Unique Epitope on Hinge Region of IgA1. Monoclon Antib Immunodiagn Immunother. 37(6):252-256, 2018.

47.Honda D, Suzuki Y. Mass media information can facilitate early diagnose of hereditary angioedema. Orphanet J of Rare Disease. 2019 in press

48.Hirano K, Matsuzaki K, YasudaT, Nishikawa M, YasudaY, Koike K, Maruyama S, Yokoo T, Matsuo S,Kawamura,T, Suzuki Y: Association between tonsillectomy and outcomes in patients with Immunoglobulin a nephropathy.
JAMA Netw　 Open. 2019;2(5): e194772doi: 10.1001/　jamanetworkopen.2019.4772

49.Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC, International IgA Nephropathy Network.：JAMA Intern Med. 2019 Apr 13. doi: 10.1001/ jamainternmed.2019.0600.

50.Neufeld M, Molyneux K, Pappelbaum KI, Mayer-Hain S, von Hodenberg C, Ehrchen J, Barratt J, Suzuki Y, Sunderkötter C: Galactose deficient IgA1 (GD-IgA1) in skin and serum from patients with skin-limited and systemic IgA Vasculitis. J Am Acad Dermatol 81(5):1078-1085,2019

51.Shimizu Y, Wakabayashi K, Hayashi Y, Hara K, Aoyama R, Niimi Y, Tomino Y, Wada R, Hata M, Suzuki Y: MPGN type 3 associated with pemphigus herpetiformis mimicking PGNMID and dermatitis herpetiformis. Case Rep Nephrol Dial. 9(1):15-24,2019

52.Wakabayashi K, Yanagawa H, Hayashi Y, Aoyama R, Shimizu Y, Tomino Y, Suzuki Y: Progressive renal dysfunction due to IgG4-related kidney disease that is refractory to steroid therapy. Case Rep Nephrol Dial. 9(1):1-7,2019

53.Shimizu Y, Wakabayashi K, Totsuka A, Hayashi Y, Nitta S, Hara K, Akira M, Tomino Y, Suzuki Y: Exercise-induced acute kidney injury (EAKI) in a police officer with hereditary renal hypouricemia. Case Rep Nephrol Dial. 9(2):92–101,2019

54.Io H, Nakata J, Aoyama R, Inoshita H, Nakano T, Ishizaka M, Fukui M, Tomino Y, Suzuki Y: Far-infrared therapy for secondary vascular access patency of hemodialysis patients. Renal Replacement Theraphy 5:30,2019

55.Koshida T, Wu S, Suzuki H, Wanchoo R, Bijol V, Tomita S, Suzuki Y, Jhaveri K: Thrombotic Microangiopathy in Dasatinib-treated patients with Chronic Myeloid Leukemia. Journal of Onco-Nephrology 1-5,2019

56.Makita Y, Suzuki H, Suzuki Y: TLR9 activation induces aberrant IgA glycosylation via APRIL-and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 97(2)340-349,2020

57.Gohda T, Kamei N, Koshida T, Kubota M, Tanaka K, Yamashita Y, Adachi E, Ichikawa S, Murakoshi M, Ueda S, Suzuki Y: Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease. J Diabetes Invest. 11(2):435-440,2020

58.Ichikawa S, Gohda T, Murakoshi M, Li Z, Adachi E, Koshida T, Suzuki Y: Aspartic Acid Supplementation Ameliorates Symptoms of Diabetic Kidney Disease in Mice. FEBS Open Bio. doi: 10.1002/2211-5463.12862, 2020

59.Hara K, Io H, Wakabayashi K, Maeda T, Kanda R, Nakata J, Maeda K, Sengoku H, Machida M, Kojima K, Sakamoto K, Tomino Y, Suzuki Y: Multicenter Laparoscopic Evaluation of the Peritoneum in Peritoneal Dialysis Patients. Semin Dial. 33(2):170-177, 2020

60.Takahata A, Arai S, Hiramoto E, Kitada K, Kato R, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y: Crucial role of AIM/CD5L in the development of glomerular inflammation in IgA. J Am Soc Nephrol., 2020 (in press)

61.Wu CY, Hua KF , Hsu WH, Suzuki Y, Chu LJ, Lee YC , Takahata　A, Lee SL , Wu CC, Nikolic-Paterson DJ , Ka SM , Chen A : IgA Nephropathy Benefits From Compound K Treatment by Inhibiting NF-κB/NLRP3 Inflammasome and Enhancing Autophagy and SIRT1. J Immunol. 2020 Jun 1;ji1900284. doi: 10.4049/ jimmunol.1900284.

62.Shirai Y, Miura K, Yabuuchi T, Nagasawa T, Ishizuka K, Takahashi K, Taneda S, Honda K, Yamaguchi Y, Suzuki H, Suzuki Y, Hattori M : Rapid Progression to End-Stage Renal Disease in a Child With IgA-dominant Infection-Related Glomerulonephritis Associated With Parvovirus B19, CEN Case Rep. 2020 Jul 3. doi: 10.1007/s13730-020-00501- w. Online ahead of print. PMID: 32621069

63.Kubo A, Hidaka T, Nakayama M, Sasaki Y, Takagi M, Suzuki H, Suzuki Y:　　Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases, BMC Nephrol.,21:402-415, 2020

64.Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, Maruyama S, Yokoo T, Matsuo S, Kawamura T, Suzuki Y: Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy, JAMA Netw Open, 2:e194772, 2020

65.Li Z, Murakoshi M, Ichikawa S, Koshida T, Adachi E, Suzuki C, Ueda S, Tomohito Gohda T, Suzuki Y: The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice, FEBS Open Bio. doi: 10.1002/2211-5463.13014, 2020

66.Io H, Nakata J , Inoshita H, Ishizaka M, Tomino Y, Suzuk Y: Relationship among left ventricular hypertrophy, cardiovascular events, and preferred blood pressure measurement timing in hemodialysis patients, J. Clin. Med. 9:3512-3521, 2020

67.Murakoshi M, Gohda T, Suzuki Y: Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease. Int J Mol Sci. 21(6):1957, 2020

68.Kobayashi T, Ueda S, Takagi M, Kihara M, Suzuki Y: Pathophysiological roles of ADMAmediated endothelial injury in hypertensive disorders of pregnancy.Hypertens Res Pregnancy,in press, 2020

69.Honda D, Ohsawa I, Mano S, Rinno H, Tomino Y, Suzuki Y： Cut-off value of C1-inhibitor function for the diagnosis of hereditary angioedema due to C1-inhibitor deficiency. Intractable Rare Dis Res,10:42-47, 2020

70.Lee M, Suzuki H, Kato R, Fukao Y, Nakayama M, Kano T, Makita Y, Suzuki Y:
Renal pathological analysis using galactose deficient IgA1-specific monoclonal antibody is a strong tool for differentiation primary IgA nephropathy from secondary IgA nephropathy, CEN Case Rep. 10:17-22, 2021

71.Kobayashi T, Ueda S, Takahashi K, Otsuka T, Nagasawa H, Yabuuchi J, Kanaguchi Y, Sugaya T, Urabe T, Tomino Y, Suzuki Y: Ischemic stroke induces rapid renal oxidative stress and lipometabolic change. Juntendo Medical Journal, 67: 39-45, 2021

72.Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Induruwage D, Er L, Reich HN, Feehally J, Barratt J, Cattran DC; International IgA Nephropathy NetworkImproving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney Int. 98:1009-1019

73.Shimizu Y, Nakata J, Yanagawa N, Shirotani Y, Fukuzaki H, Nohara N, Suzuki Y: Emergent initiation of dialysis is related to an increase in both mortality and medical costs. Sci Rep. 10:19638, 2020

74.Yabuuchi J, Ueda S, Yamagishi S, Nohara N, Nagasawa H, Wakabayashi K, Matsui T, Higashimoto Y, Kadoguchi T, Otsuka T, Gohda T, Suzuki Y: Assosiation of advanced glycation end products with sarcopenia and frailty in chronic kidney disease. Sci Rep. 10:17647, 2020

75.Kuwasawa-Iwasaki M, Io H, Muto M, Ichikawa S, Wakabayashi K, Kanda R, Nakata J, Nohara N, Tomino Y, Suzuki Y: Effects of L-Carnitine Supplementation in Patients Receiving Hemodialysis or Peritoneal Dialysis. Nutrients. 12(11):3371, 2020

76.Shimizu Y, Nakata J, Maiguma M, Shirotani Y, Fukuzaki H, Nohara N, Io H, Suzuki Y: Predictive Value of 1-Week Postoperative Ultrasonography Findings for the Patency Rate of Arteriovenous Fistula. Kidney Int Rep. 5(10):1746-1752, 2020

77.Nakayama M, Hamada C, Yokoyama K, Tanno Y, Matsuo N, Nakata J, Ishibashi Y, Okuzawa A, Sakamoto K, Nara T, Kakuta T, Nangaku M, Yokoo T, Suzuki Y, Miyata T: A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity. Sci Rep. 10(1):17565, 2020

78.Yang SR, Hua KF, Takahata A, Wu CY, Hsieh CY, Chiu HW, Chen CH, Mukhopadhyay D, Suzuki Y, Ka SM, Huang HS, Chen A: LCC18, a benzamide-linked small molecule, ameliorates IgA nephropathy in mice. J Pathol. 253(4):424-441, 2020

79.Gohda T, Kamei N, Kubota M, Tanaka K, Yamashita Y, Sakuma H, Kishida C, Adachi E, Koshida T, Murakoshi M, Hagiwara S, Funabiki K, Ueda S, Suzuki Y: Fractional excretion of TNF receptor 1 and 2 in patients with type 2 diabetes and normal renal function. J Diabetes Investig. 12(3):382-389, 2021

80.Nihei Y, Nagasawa H, Fukao Y, Kihara M, Ueda S, Gohda T, Suzuki Y: Continuous extracorporeal treatments in a dialysis patient with COVID-19. CEN Case Rep. 10(2):172-177, 2021

81.Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N, Huang ZQ, Knoppova B, Khan A, Hall S, Yanagawa H, Brown R, Winstead CJ, O'Quinn DB, Weinmann A, Gharavi AG, Kiryluk K, Julian BA, Weaver CT, Suzuki Y, Novak J: Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J Autoimmun. 118:102593，2021

82.Han W, Suzuki T, Watanabe S, Nakata M, Ichikawa D, Koike J, Oda T, Suzuki H, Suzuki Y, Shibagaki Y: Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis. Medicine (Baltimore). 5;100(5):e24460, 2021

83.Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, Matsuzaki K, Suzuki Y, Katafuchi R, Reich HN, Cattran D, International IgA Nephropathy Network: Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. J Am Soc Nephrol. 32(2)436-447, 2021

84.Matsuzaki K, Suzuki H, Kawamura T, Tomino Y, Suzuki Y: Utility of remission criteria for the renal prognosis of IgA nephropathy. Clin Exp Nephrol. in press

85.Kano T, Suzuki H, Makita Y, Fukao Y, Suzuki Y: Nasel-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. Kidney Int. 5: S0085-2538(21)00467-1, 2021

86.Yang SR, Hua KF, Takahata A, Wu CY, Hsieh CY, Chiu HW, Chen CH,　Mukhopadhyay D, Suzuki Y, Ka SM, Huang HS, Chen A: LCC18, a benzamide-linked small molecule, ameliorates IgA nephropathy in mice. J Pathol. 253:427-441, 2021

87.Gohda T, Yanagisawa N, Murakoshi M, Ueda S, Nishizaki Y, Nojiri S, Ohashi Y, Ohno I, Shibagaki Y, Imai N, Iimuro S, Kuwabara M, Hayakawa H, Kimura K, Hosoya T, Suzuki Y: Association between kidney function decline and baseline TNFR levels or change ratio in TNFR by febuxostat chiefly in non-diabetic CKD patients with asymptomatic hyperuricemia. Front Med. 8:634932, 2021

88.Nagasawa H, Ueda S, Otsuka T, Kaifu K, Ono S, Okuma T, Kobayashi T, Matsushita S, Kasai T, Dohi T, Fukushima Y, Amano A, Suzuki Y: Safety and efficacy of using cereal food　(Frugra®) to improve blood pressure and bowel health in patients undergoing chronic hemodialysis: A pilot study. J Pharmacol Sci. 147:132-137, 2021

89.Fukao Y, Nagasawa H, Nihei Y, Hiki M, Naito T, Kihara M, Gohda T, Ueda S, Suzuki Y: COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine. Clin Exp Nephrol. 25:1240-1246, 2021

90.Akira M, Suzuki H, Ikeda A, Iwasaki M, Honda D, Takahara H, Rinnno H, Tomita S, Suzuki Y: Atypical histological abnormalities in an adult patient with nephronophthisis harboring NPHP1 deletion. BMC Nephrol. 22:261, 2021

91.Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejia-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JSF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J: Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 100:753-779, 2021

92.Suzuki H, Kikuchi M, Koike K, Komatsu H, Matsuzaki K, Takahashi K, Ichikawa D, Okabe M, Obata Y, Katafuchi R, Kihara M, Kohatsu K, Sasaki T, Shimizu A, Nakanishi K, Fukuda A, Miyazaki Y, Muto M, Yanagawa H, Suzuki Y, Fujimoto S, Furuichi K, Okada H, Narita I: A digest from evidence-based clinical practice guideline for IgA nephropathy 2020. Clin Exp Nephrol. 25:1269-1276, 2021

93.Murakoshi M, Gohda T, Adachi E, Ichikawa S, Hagiwara S, Suzuki Y: Differential organ-specific inflammatory response to progranulin in high-fat diet-fed mice. Sci Rep. 11:1194, 2021

94.Usui N, Yokoyama M, Nakata J, Suzuki Y, Tsubaki A, Kojima S, Inatsu A, Hisadome H, Uehata A: Association between social frailty as well as early physical dysfunction and exercise intolerance among older patients receiving hemodialysis. Geriatr Gerontol Int. 21:664-669, 2021

95.Ueno Y, Saito A, Nakata J, Kamagata K, Taniguchi D, Motoi Y, Io H, Andica C, Shindo A, Shiina K, Miyamoto N, Yamashiro K, Urabe T, Suzuki Y, Aoki S, Hattori N: Possible Neuroprotective Effects of l-Carnitine on White-Matter Microstructural Damage and Cognitive Decline in Hemodialysis Patients. Nutrients. 13:1292, 2021

96.Fukuzaki H, Nakata J, Shirotani Y, Shimizu Y, Maiguma M, Nohara N, Suzuki Y: An Unusual Case of Recurrent Migration of the Peritoneal Dialysis Catheter into the Inguinal Hernia Sac. Case Rep Nephrol Dial. 11:152-157, 2021

97.Shimizu Y, Wakabayashi K, Iwasaki H, Kishida C, Seki S, Okuma T, Iwakami N, Iwasawa T, Maekawa H, Tomino Y, Wada R, Suzuki Y: Immunotactoid Glomerulopathy with Nontuberculous Mycobacterial Infection: A Novel Association. Case Rep Nephrol Dial. 11:136-146, 2021

98.Zambrano S, He L, Kano T, Sun Y, Charrin E, Lal M, Betsholtz C, Suzuki Y, Patrakka J: Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing. Kidney Int. 101(4):752-765, 2022

99.Fukuzaki H, Nakata J, Nojiri S, Shimizu Y, Kano T, Shirotani Y, Maeda T, Nohara N, Io H, Suzuki Y: Negative-pressure wound therapy is effective for peritoneal dialysis catheter exit-site management in the early postoperative period. Sci Rep. 12(1):70, 2022

100.Matsuzaki K, Aoki R, Nihei Y, Suzuki H, Kihara M, Yokoo T, Kashihara N, Narita I, Suzuki Y: Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 26(4): 316-322, 2022

101.Ishida M, Matsuzaki K, Ikai H, Suzuki H, Kawamura T, Suzuki Y: Cost analysis of screening for IgA nephropathy using novel biomarkers. Value Health Reg Issues. 29:8-15, 2022

102.Usui N, Uehata A, Nakata J, Inatsu A, Tsubaki A, Saitoh M, Izumi T, Chiba Y, Kojima S, Suzuki Y: Effect of blood volume change related to intensity of intradialytic aerobic exercise on hemodialysis adequacy: a pilot study. Int Urol
Nephrol. 54(6): 1427-1434, 2022

103.Barratt J, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, Jin H, Gühring H, Appel G, on behalf the JANUS study investigators: Atacicept in patients with immunoglobulin A nephropathy and persistent proteinuria: results of the randomized, double-blind, placebo-controlled Phase Ⅱ JANUS study. Kidney Int Rep. 7(8):1831-1841, 2022

104.Barratt B, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, Jin H, Gühring H, Appel G, JANUS study investigators: Randomized Phase II JANUS Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Kidney Int. 7:1831-1841, 2022

105.Joh K, Nakazato T, Hashiguchi A, Shimizu A, Katafuchi R, Okonogi H, Koike K, Hirano K, Tsuboi N, Kawamura T, Yokoo T, Narita I, Suzuki Y: Structural modeling for Oxford histological classifications of immunoglobulin A nephropathy. PLoS One. 17(9): e0268731, 2022

106.Murakoshi M, Gohda T, Sakuma H, Shibata T, Adachi E, Kishida C, Ichikawa S, Koshida T, Kamei N, Suzuki Y: Progranulin and Its Receptor Predict Kidney Function Decline in Patients with Type 2 Diabetes. Front Endocrinol (Lausanne). 13:849457, 2022

和文原著
1.富野康日己、淺沼克彦、井尾浩章、鈴木　仁、田中裕一、中田純一郎、小林則善、武田之彦、稲見裕子、清水芳男、柘植俊直、鈴木祐介、大澤　勲、来栖　厚、濱田千江子、堀越　哲、若林道郎、青木竜弥、金口泰彦、彰　一祐：高カリウム血症を伴う慢性腎臓病（ＣＫD）患者に対するポリスチレンスルホン酸カルシウムゼリーの長期投与効果の検討Ther. Res. 31:1471-1480, 2010

2.高良勝彦、鈴木　仁、鈴木祐介、堀越哲、富野康日己：慢性腎臓病を伴う高血圧患者に対する塩酸ベニジピンの尿蛋白改善効果作用並びに抗酸化作用 –未治療高血圧患者における層別解析研究- 順天堂医学57: 610-616, 2011

3.佐々木洋平、大澤　勲、中田純一郎、小林則善、荻島達也、藤目　真、伊藤浩一、荒川　　敦、八尾隆史、鈴木祐介、来栖　厚、堀越　哲、富野康日己：頭痛と低カルシウム血症を呈した原発性アルドステロン症に対して病側副腎摘除術を施行した１症例順天堂医学 57: 644-649, 2011

4.松尾清一、川村哲也、鈴木祐介ら　厚生労働科学研究費補助金難治性疾患克服研究事業　進行性腎障害に関する調査研究班報告IgA腎症分科会：IgA腎症の寛解基準の提唱　日腎会誌　55(7)、2013

5.村越真紀、苑田祐二、丸山俊太郎、鈴木仁、鈴木祐介、堀越哲、合田朋仁：　高血圧患者におけるテルミサルタンが炎症・腎機能マーカーに与える影響　　血圧　23: 56-60, 2016

6.濱田千江子、野原奈緒、中田純一郎、町田修一、中潟崇、内藤久士、鈴木祐介 : リストバンド型加速度センサー付ライフログレコーダを使った透析患者の身体活動の評価. 日本透析医会雑誌. 33(1) : 157-162, 2018

7.井尾浩章、中田純一郎、青山留未、井下博之、中野貴則、石坂匡則、福井光峰、富野康日己、鈴木祐介：血液透析患者の内シャント狭窄予防における遠赤外線照射治療の有用性　日本透析医会雑誌　33（2）：321-324，2018

8.神田怜生、井尾浩章、中田純一郎、富野康日己、鈴木祐介：腹膜透析患者における腹膜障害と心血管病イベント発症予測因子としての新規マーカー：Pentraxin3（PTX3）に関する研究　日本透析医会雑誌　36: 135-140, 2021

英文総説
1.Tomino Y, Suzuki Y, Tsuge T, Ohmuro H, Suzuki S, Fukui M, Shirato I: IgA nephropathy pathogenesis and treatment. J Nephrol Dial Transplant 6: 518-524, 1997

2.Ruiz-Ortega M, Lorenzo O, Suzuki Y, Gatica A, and Egido J: Role of the renin-angiotensin system in the progression of renal disease. Nephrologia 1: 50, 2000

3.Egido J, Hernandez-Presa MA, Tunon J, Blanco-Colio LM, Ortego M, Suzuki Y, Plaza JJ, Guijarro C: Transcriptional factor kB (NF-kB) and cardiovascular disease. Cardiovascular risk factors 9: 159-168, 2000

4.Suzuki Y, Ruiz-Ortega M, Egido J: Angiotensin II: a double-edged sword in inflammation. J Nephrol. Suppl 3: S101-110, 2000

5.Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, and Egido J: Proinflammatory actions of Angiotensin II. Current Opin of Hypertension and Renal Disease 10: 321-329, 2001

6.Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J: Role of the Renin-Angiotensin system in vascular diseases: expanding the field. Hypertension 38: 1382-1387, 2001

7.Gomez-Guerrero C, Suzuki Y, Egido J: Identification of IgA receptors in human mesangial cells. In the search for “El Dorado”. Kidney Int 62: 715-717, 2002

8.Ruiz-Ortega M, Alcazar R, Ruperez M, Suzuki Y, Esteban V, Rodriguez-Vita J, sanchez-Lopez E, Egido J: Inflamacion y angiotensin II en la fisiopatologia del dano vascular diabetico. Med Clin 118: 1-12, 2002

9.Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Estevan V, Egido J: Inflammation and angiotensin II. Int Biochem Cell Biol 35: 881-900, 2003

10.Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, Tomino Y and Egido J: Angiotensin II and renal diseases: what is the involvement of the immune system? Nephrol Dial Transpant 18: 1423-1426, 2003

11.Caramelo C, Alvarez-Arroyo MV, Yague S, Suzuki Y, Castilla MA, Velasco L, Gonzalez-Pacheco FR, Tejedor A: Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward. Nephrol Dial Transpant 19: 285-288, 2004

12.Tomino Y, Tsuge T, Suzuki Y, Gu L, Tanimoto M, Gohda T, Horikoshi S: Basic research in progressive glomerulopathies: The role of fibrosing factors in IgA nephropathy and diabetic nephropathy. Kidney Int 94: s92-95, 2005

13.Suzuki Y, Tomino Y: Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: insights from animal models. Semin Nephrol 28: 66-77, 2008

14.Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, Tomino Y: Pathological role of tonsillar B cells in IgA nephropathy. Clin Dev Immunol:　639074, 2011

15.Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Mestecky J, Suzuki H: Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol 72: 60-63, 2011

16.Suzuki Y, Suzuki H, Sato D, Kajiyama T, Okazaki K, Hashimoto A, Kihara M, Yamaji K, Satake K, Nakata J, Aizawa M, Novak J, Tomino Y: Reevaluation of the mucosa-bone marrow axis in IgA nephropathy with animal models. Adv Otorhinolaryngol 72: 64-67, 2011

17.Suzuki Y, Suzuki H, Makita Y, Takahata A, Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H, Okazaki K, Tomino Y: Diagnosis and activity assessment of IgA nephropathy: current perspectives on non-invasive testing with aberrantly glycosylated IgA-related biomarkers. Int J Nephrol and Renovasc Dis 7: 409-414, 2014

18.Suzuki H, Suzuki Y, Novak J, Tomino Y: Development of Animal Models of Human IgA Nephropathy. Drug Discov Today Dis Models 11: 5-11, 2014

19.Suzuki Y, Suzuki H, Yasutake J, Tomino Y: Paradigm shift in activity assessment of IgA nephropathy–optimizing the next generation of diagnostic and therapeutic maneuvers via glycan-targeting. Expert Opin Biol Ther 20: 1-11, 2015.

20.Hagiwara　S, Gohda T, Funabiki K, Suzuki Y: Essential points of treatment and examination to prevent diabetic kidney disease aggravation. Juntendo Medical Journal. 65(6):529-536,2019

21.Okonogi H, Kawamura T, Joh K, Koike K, Miyazaki Y, Ogura M, Tsuboi N, Hirano K, Matsushima M, Yokoo T, Horikoshi S, Suzuki Y, Yasuda T, Shirai S, Shibata T, Hattori M, Akioka Y, Katafuchi R, Hashiguchi A, Hisano S, Shimizu A, Kimura K, Maruyama S1, Matsuo S, Tomino Y; Special IgA Nephropathy Study Group.: A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clin Exp Nephrol 23(1):16-25, 2019

22.Murakoshi M, Gohda T, Suzuki Y: Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease. Int J Mol Sci. 21:1957, 2020

23.Kobayashi T, Ueda S, Takagi M, Kihara M, Suzuki Y: Pathophysiological roles of ADMAmediated endothelial injury in hypertensive disorders of pregnancy. Hypertens Res Pregnancy. 8:40-46, 2020

24.Yap DYH, McMahon LP, Hao CM, Hu N, Okada H, Suzuki Y, Kim SG, Lim SK,　Vareesangthip K, Hung CC, Nangaku M, APSN HIF-PHI Recommendation Committee: Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors. Nephrology (Carlton). 26(2):105-118, 2020

25.Sakuma H, Hagiwara S, Kantharidis P, Gohda T, Suzuki Y: Potential Targeting of Ranal Fibrosis in Diabetic Kidney Disease Using MicroRNAs. Front Pharmacol. 11:587689, 2020

26.Suzuki Y, Monteiro RC, Coppo R, Suzuki H: The phenotypic of IgA nephropathy and its race- and gender-dependent molecular mechanisms. Kidney 360. 2:1339-1348, 2021

27.Monteiro RC, Suzuki Y: Are there animal models of IgA nephropathy? Semin Immunopathol. 43:639-648, 2021

28.Salsabila SA, Rosyid AN, Empitu MA, Kadariswantiningsih IN, Suryantoro SD, Haryati MR, Thaha M, Suzuki Y: Kidney-pulmonary Crosstalk from A Pathophysiological Perspective. J. Respi. 8:44-51, 2022

総説
1.鈴木祐介、富野康日己：貧血管理、至適Hb値と鉄剤の功罪　内科 104:61-65, 2009

2.鈴木祐介、富野康日己：　糸球体腎炎（IgA腎症を含む）内科疾患の診断基準・病型分類・重症度　内科　105:1091-1095, 2010

3.鈴木祐介、富野康日己：CKDの診断　尿検査　腎と透析 69（増刊号）:41-44, 2010

4.鈴木祐介：ONTARGET試験への評価・コメント　Nephrology Frontier 9:72, 2010

5.鈴木祐介、鈴木仁、佐藤大介、梶山忠弘、渡辺智成、富野康日己：IgA腎症とSchoenlein Henoch紫斑病　腎と透析　70:73-76, 2010

6.鈴木祐介、富野康日己：　結節性多発動脈炎　医学と薬学65:313-317, 2011

7.鈴木祐介：IgA腎症に関する臨床上の問題点―成因からみた治療の体系化―　炎症と免疫 19:111-115, 2011

8.鈴木祐介：くるみ割り人形症候群　「知っておきたい内科症候群」内科　109:1407-1410, 2012

9.川村哲也、鈴木祐介：CKD関連ガイドラインを臨床に活かす　IgA腎症　Nephrology Frontier 11: 2012 (in press)

10.鈴木祐介：IgA腎症のバイオマーカーと治療戦略　―根治治療開発のための条件― 医薬ジャーナル 2012 (in press)

11.鈴木仁、鈴木祐介、富野康日己：IgA腎症患者扁桃とTLR　Annual Review2013 腎臓:47-56, 2013

12.鈴木祐介、富野康日己：IgA腎症とステロイド療法　臨床と研究　90 (7), 2013

13.鈴木祐介、富野康日己：IgA腎症のステロイド療法のUp to date　カレントテラピー　31 (6), 2013

14.鈴木祐介：学会レポート　第58回日本透析医学会学術集会・総会　腎・高血圧の最新治療　2013

15.鈴木祐介、富野康日己：IgA腎症の病態における扁桃B細胞の役割　「今明らかにされた扁桃とIgA腎症を結びつけるエビデンス：腎臓内科学、病理学、耳鼻咽喉科学のアプローチから」　口腔・咽頭科　2013　

16.鈴木祐介、鈴木仁、柳川宏之、松崎慶一、牧田郁子、高畑曉子、富野康日己：IgA腎症の新しいバイオマーカー　腎と透析：76; 31-35, 2014

17.鈴木祐介、富野康日己：特集　腎臓学この一年の進歩2013：腎炎・ネフローゼ症候群」　日本腎臓学会誌: 56:14-21, 2014

18.鈴木仁、鈴木祐介：「IgA腎症早期発見のための新規バイオマーカーを用いた血尿の２次スクリーニングの試み」腎・高血圧の最新治療　2015

19.高畑曉子、鈴木祐介：IgA腎症における性差ー性ホルモンの関与―　腎臓内科・泌尿器科　1:485-490, 2015

20.鈴木仁、木原正夫、鈴木祐介: IgA腎症とIgA血管炎の共通病態東京内科医会会誌 33:169-170, 2017

21.鈴木祐介：【糸球体腎炎】粘膜免疫異常とIgA腎症　日本腎臓学会誌　58:648-655, 2016

22.鈴木仁、木原正夫、鈴木祐介: IgA腎症とIgA血管炎の共通病態東京内科医会会誌 33:169-170, 2017

23.狩野俊樹、鈴木仁、鈴木祐介：【腸管細菌叢と腎疾患】腸管粘膜免疫異常と腸腎関連　日本腎臓学会会誌　59:552-556，2017

24.木原正夫、鈴木祐介：IgA腎症治療の国際比較. 腎臓内科・泌尿器科. 7:84-88, 2018

25.狩野俊樹、鈴木祐介：【腎疾患診療の未来　最新知見のエッセンシャル: 腎疾患の疫学・病因の研究の進歩】IgA腎症の発症機構. 診断と治療. 106:423-428, 2018

26.日高輝夫、鈴木祐介：【疾患・病態を理解する-尿沈渣レファレンスブック：腎疾患-症候群と尿沈渣成分】ネフローゼ症候群. 臨床検査. 62:462-463, 2018

27.井尾浩章、野原奈緒、井下博之、中野貴則、石坂匡則、鈴木祐介：早期慢性腎臓病(CKD stage 1-3)患者の透析導入に関連する因子の検討練馬医学会誌　24:84–87,2018

28.出崎雄也、鈴木祐介：【腎と透析ベッドサイド検査事典】 (第11章)免疫血清学的検査　免疫グロブリン　クリオグロブリン定性　腎と透析増刊号84:338-340,2018

29.鈴木仁、鈴木祐介：【血管炎とアレルギー疾患 -内因性・外因性アジュバントの関わり-】 Tonsil induced autoimmune/inflammatory syndrome(TIAS)としてのIgA腎症　アレルギー・免疫　25：802‐809,2018

30.井尾浩章、若林啓一、神田怜生、中田純一郎、井下博之、中野貴則、石坂匡則、鈴木祐介：HD導入時のシャント管理　心機能とシャント血流を評価する　腎と透析別冊腎不全外科2018　84：59-62, 2018

31.二瓶義人、鈴木祐介：【特殊：腎臓病のエンドポイント】IgA　腎症の病態から考えるエンドポイント　The endpoint based on the pathogenesis of IgA nephropathy　日本腎臓学会誌　60：592-596, 2018

32.禾千絵子、鈴木祐介：【血管炎(第2版)-基礎と臨床のクロストーク-】小型血管炎　IgA血管炎　疫学・病態　日本臨床　76：388-392, 2018

33.鈴木仁、鈴木祐介：Gd-IgA1(糖鎖異常IgA1)モノクローナル抗体　腎・高血圧の最新治療　7：144-147, 2018

34.禾千絵子、鈴木仁、鈴木祐介：IgA腎症の発症機序から考える治療の妥当性　IgA腎症の臨床　Clinical medicine of IgA nephropathy　2-7, 2018

35.鈴木仁、鈴木祐介：IgA腎症の新規分子標的薬の可能性　IgA腎症の臨床　Clinical medicine of IgA nephropathy　187-189, 2018

36.鈴木仁、鈴木祐介: Tonsil indeuced autoimmune/　inflammatorysyndrome(TIAS)としてのIgA腎症. ｱﾚﾙｷﾞｰ・免疫　Allergology & Immunology Vol.25 No.6. 25(6): 76-83, 2018

37.狩野俊樹、鈴木祐介：【腸内細菌叢と腎泌尿器疾患】腎におよぼす腸管免疫の作用　腎臓内科・泌尿器科　7：533-538，2018

38.狩野俊樹、鈴木祐介：扁桃活性化機序からみたIgA腎症　医学のあゆみ　267：236-238，2018

39.佐藤大介、鈴木祐介：【CKD(慢性腎臓病)慢性腎臓病のこれまと今後：最新の実地診療のポイントの整理と活用】IgA腎症の診断と治療 Medical Practice 35 （10）：1547-1552,2018

40.合田朋仁、鈴木祐介: 【糖尿病性腎症と糖尿病性腎臓病:最近の進歩】酸化ストレスをターゲットとした治療：バルドキソロンメチルへの期待月間糖尿病月間糖尿病 10 (8)：86-93,2018

41.小林敬、鈴木祐介: 【特集：臨床検査と総合健診】慢性腎臓病治療における健康診断の重要性総合健診日本総合健診医学会誌 46（2）：22-23,2019

42.中田純一郎、鈴木祐介: IgA腎症 -根治治療開発に求められること腎・高血圧の最新治療 8(2)：68-73,2019

43.木原正夫、鈴木祐介：【特集：IgA腎症-診断・治療の最新動向-】 IgA腎症診療の現況と展望　日本臨床　77（4）：588-592,2019

44.狩野俊樹、鈴木祐介：【特集：IgA腎症-診断・治療の最新動向-】 IgA腎症の病因・病態生理　IgA腎症と粘膜免疫　日本臨床　77（4）：620-624,019

45.牧田侑子、鈴木祐介：【特集：腎疾患の重症化予防-現状と将来】IgA腎症重症化予防-現状と将来　医学と薬学　76（7）：975-979,2019

46.鈴木仁、鈴木祐介：【特集：今、糸球体疾患を考える】一次性糸球体疾患　IgA腎症：新規バイオマーカーを用いた早期診断と活動性評価　腎と透析　86（5）：531-534,2019

47.深尾勇輔、鈴木祐介：【特集：今、糸球体疾患を考える】一次性糸球体疾患　IgA腎症：病因としての粘膜関連リンパ組織　腎と透析　86（5）：527-530,2019

48.塩田遼太郎、鈴木祐介：【第1章　膠原病、血管炎、自己免疫疾患】IgA血管炎・腎臓専門医の視点より　腎と透析　86：109-112,2019

49.牧田侑子、鈴木祐介：【解説】BAFF/APRIL　腎臓内科　11（1）：78-83,2020

50.足立恵理、村越真紀、合田朋仁、鈴木祐介：新規DKD治療薬としてのASK1阻害薬（Selonsertib）への期待　Pharma Medica　 38：63-67,2020

51.毎熊政行、鈴木祐介：IgA腎症の新展開　腎臓内科　12（4）：1-6,2020

52.大塚智之、上田誠二、鈴木祐介：【特集：糖脂質代謝連関と老年病】1.ADMAと心腎連関　The　Lipid　 31（2）：14-20,2020

53.中山麻衣子、鈴木祐介：IgA腎症　生体の科学　71(5)： 2-3,2020

54.鈴木仁、鈴木祐介：腎臓病学この1年の進歩　IgA腎症の病態　日本腎臓学会誌　62: 26-33,2020

55.長澤肇、上田誠二、鈴木祐介：腎臓病　CURRENT THERAPY　39: 53-57, 2021

56.小林敬、鈴木祐介: 糸球体疾患　指定難病としてのIgA腎症の現状と病態腎と透析 91: 55-59, 2021

57.大塚智之、上田誠二、鈴木祐介: 腎臓専門医への紹介のタイミング内科 128: 971-973, 2021
43. 鈴木祐介、二瓶義人、鈴木仁: 医学と医療の最前線　IgA腎症の最新治療とその背景日本内科学会雑誌 110: 2286-2292, 2021

58.佐藤浩司、上田誠二、鈴木祐介：職場高血圧　臨床栄養　138(3):　373-377, 2021

59.毎熊政行、鈴木祐介: IgA腎症　日本臨牀　79:　1873-1879, 2021

英文著書
1.Suzuki Y, Tomino Y: Experimental model of IgA nephropathy. Monograph on IgA nephropathy. London, 2008

2.Suzuki Y. Coppo R, Tomino Y: Beyond the differences in tonsillectomy in IgA nephropathy: from rationale to indications in patients. Pathogenesis and treatment in IgA nephropathy. Tomino Y(Ed), Springer, Tokyo, Japan, 2016

和文著書
1.鈴木祐介:「慢性腎炎症候群（無症候性蛋白尿・血尿を含む）」　今日の治療指針2010年版　山口徹、北原光男、福井次矢（編）、医学書院、東京、2010

2.鈴木祐介:「 IgA腎症に対する扁桃摘出術のEBMとは？　腎臓内科の立場から」　EBM 耳鼻咽喉科・頭頸部腫瘍の治療　2010-2011　池田勝久、武田憲明、原渕保明、丹生健一（編）、中外医学社、東京、2010

3.富野康日己、鈴木祐介、鈴木仁：「IgA腎症の病因に関わるMucosa-Bone Marrow Axisの異常」　臨床粘膜免疫学　清野宏(編)、シナジー、東京、2011

4.鈴木祐介:「蛋白尿を抑制・減少させる薬剤はないのですか？」　生活習慣病・腎臓病・高血圧対策Q&A―みなさんの質問にお答えします　富野康日己（編）、中外医学社、東京、2011

5.鈴木祐介: 「ネフローゼ症候群ってどういう病気ですか？」　生活習慣病・腎臓病・高血圧対策Q&A―みなさんの質問にお答えします　富野康日己（編）、中外医学社、東京、2011

6.鈴木祐介: 「健康診断で毎回尿潜血反応陽性で、遊走腎といわれました。この先、腎機能が低下する可能性はありますか？」　生活習慣病・腎臓病・高血圧対策Q&A―みなさんの質問にお答えします　富野康日己（編）、中外医学社、東京、2011

7.鈴木祐介: 「IgA腎症の発症・進展メカニズム　IgA腎症の発症機序」IgA腎症診療マニュアル　第３版　富野康日己（編）、南江堂、東京、2011

8.鈴木祐介:「アデノシンジアミナーゼ」　臨床検査基準値express　富野康日己（編）、中外医学社、東京、2011

9.鈴木祐介:「イソクエン酸脱水素酵素」　臨床検査基準値express　富野康日己（編）、中外医学社、東京、2011

10.鈴木祐介:「グアナーゼ」　臨床検査基準値express　富野康日己（編）、中外医学社、東京、2011

11.鈴木祐介:「LCAT」　臨床検査基準値express　富野康日己（編）、中外医学社、東京、2011

12.鈴木祐介:「血中、尿アミラーゼ、アイソザイム」　臨床検査基準値express　　富野康日己（編）、中外医学社、東京、2011

13.鈴木祐介:「IgA腎症の発症、進展機序の理解はどこまで進んだのでしょうか？」　EBM腎臓病学の治療2011-2012　柏原直樹、南学正臣（編）、中外医学社、2011

14.鈴木祐介:「IgA腎症の発症には何らかのアレルギー素因が関与するのでしょうか？」　IgA腎症診療指針Q&A 富野康日己、川村哲也（編）松尾清一（監修）、診断と治療社、東京、 2011

15.鈴木祐介:「IgA腎症の進展機序のうち、免疫学的機序について教えてください」　IgA腎症診療指針Q&A 富野康日己、川村哲也（編）松尾清一（監修）、診断と治療社、東京、2011

16.鈴木祐介:「IgA腎症発症の地域差と腎生検の時期」　IgA腎症診療指針Q&A 富野康日己、川村哲也（編）松尾清一（監修）、診断と治療社、東京、2011

17.鈴木祐介:「IgA腎症とはどういう疾患ですか？」　CKD診療連携―Evidence & Tips―　富野康日己（編）、中外医学社、東京、2012

18.鈴木祐介:「IgA腎症での扁桃摘出術とステロイドパルス併用療法とは何ですか？」　CKD診療連携―Evidence & Tips―　富野康日己（編）、中外医学社、東京、2012

19.鈴木祐介:「透析の医療保険はどうなっていますか？」　ナーシングケアQ&A　富野康日己（編）、総合医学社、東京、2012

20.鈴木祐介：「脂質異常症（高脂血症）が腎臓病・血圧に悪い理由は何ですか？」　腎臓病・高血圧と薬剤　実践Q&A、富野康日己（編）、中外医学社、東京、　2013

21.鈴木祐介：「高尿酸血症は、どうして腎臓に悪いのですか？腎臓が悪いから高尿酸血症になるのですか？」　腎臓病・高血圧と薬剤　実践Q&A　富野康日己（編）、中外医学社、東京、2013

22.鈴木祐介：「高尿酸血症は、どうして腎臓に悪いのですか？腎臓が悪いから高尿酸血症になるのですか？」　腎臓病・高血圧と薬剤　実践Q&A、富野康日己（編）、中外医学社、東京、2013

23.鈴木祐介：「低尿酸血症は、どうして腎臓に悪いのですか？」　腎臓病・高血圧と薬剤　実践Q&A　富野康日己（編）、中外医学社、東京、2013

24.鈴木祐介、増田稔：「有病者の栄養管理　慢性腎臓病（ＣＫＤ）ネフローゼ症候群」　スマート栄養管理術１００－栄養管理が重要であるこれだけの理由　富野康日己（編）、医歯薬出版、東京、2014

25.鈴木祐介、増田稔：「有病者の栄養管理　慢性腎臓病（ＣＫＤ）ネフローゼ症候群」　スマート栄養管理術１００－栄養管理が重要であるこれだけの理由　富野康日己（編）、医歯薬出版、東京、2014

26.鈴木祐介：「IgA腎症、紫斑病性腎炎」　今日の治療指針2015　福井次矢、高木誠、小室一誠（編）、医学書院、東京、2014

27.鈴木祐介：「4)IgA腎症」　Newエッセンシャル　富野康日己（編）、腎臓内科学、医歯薬出版、東京、134-146　2015

28.鈴木祐介：井尾浩章：「III．症候・病態編　排尿痛」、内科診断学　第３版　福井次矢、奈良信雄（編）、医学書院、東京、617-621　2016

29.鈴木祐介：「②血尿」　内科外来診断NAVI 2016、中外医学社、東京

30.高橋敬子、鈴木祐介：「6.IgA腎症（成人）：ステロイド療法の適応と実際」腎疾患・透析　最新の治療　2017-2019、山縣邦弘、南学正臣（編）、南江堂、東京、2017

31.佐藤大介、鈴木祐介: 【CKD(慢性腎臓病)慢性腎臓病のこれまでと今後：最新の実地診療のポイントの整理と活用】IgA腎症の診断と治療、Medical Practice、文光堂、東京、l35（10）：1547-1552,2018

32.長澤肇、上田誠二、鈴木祐介：「10.ADMA,SDMA」、透析患者の検査値の読み方、深川雅史（監修）、日本メディカルセンター、4：254-255,2018

33.禾千絵子、鈴木仁、鈴木祐介：IgA腎症の発症機序から考える治療の妥当性　IgA腎症の臨床、Clinical medicine of IgA nephropathy、2-7, 2018.

34.鈴木仁、鈴木祐介：IgA腎症の新規分子標的薬の可能性　IgA腎症の臨床 Clinical medicine of IgA nephropathy　187-189, 2018

35.鈴木祐介: 【8章腎・泌尿器疾患】2.　慢性糸球体腎炎今日の処方　改訂第6版南江堂 328-329,2019

36.長澤肇、上田誠二、鈴木祐介: 【5章　血液生化学（代謝、内分泌）】　10.ADMA、SDMA 透析患者の検査値の読み方　第4版日本メディカルセンター 254-255,2019

37.木原正夫、鈴木祐介：【B.糸球体疾患】10.IgA腎症およびIgA血管炎（Henoch-Schoenlein purpura紫班病）、プロフェッショナル腎臓病学、南学正臣（編著）、中外医学社、183-194, 2020

38.小林敬、鈴木祐介：腎機能悪化の危険性が高いのはどのような患者ですか？、　わかる！できる！腎臓リハビリテーション　Q＆A、医歯学出版㈱、36-37, 2021

39.小林敬、鈴木祐介：1)IgA腎症　IgA腎症の診断や活動性評価はどのように行いますか？、腎臓病診療Q＆A AKI～CKD～腎難病まで、山縣邦弘（監修）、東京医学社、182-183、2021

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

鈴木 祐介（スズキ ユウスケ）

鈴木祐介（スズキユウスケ）